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ABSTRACT 
 
 
Type 1 diabetes (T1D) is an autoimmune disease characterized by the destruction 
of insulin-secreting pancreatic β-cells in genetically susceptible individuals, whose 
incidence is increasing worldwide. So far, our ability to curb this pathogenic 
immune response is limited by the poor understanding of the exact nature and 
kinetics of the immunological mechanisms leading to T1D. Indeed, triggers of islet 
autoimmunity and the precise mechanisms responsible for the progressive β-cell 
failure are not completely understood. Several scientific evidence supports a 
crucial role for the environment, which is also suggested by the rapid increase of 
incidence of this autoimmune disease. The search for a single cause of T1D has 
been vain, more probably there are a number of different factors that may 
contribute either to the initiating of the disease process or precipitating the 
manifest disease in subjects on their way to get diabetes. High living standard, 
good parent education, few siblings, pronounced hygiene, are all factors with 
possible important effects on immune system and autoimmune risk. In addition, 
the recent escalation of obesity in affluent countries has been suggested to 
contribute to the increased incidence of T1D, as a precipitating factor. 
Understanding the link between metabolism and immune tolerance could lead to 
the identification of new markers for the monitoring of disease onset and 
progression. We studied several immune cell subsets and factors with high 
metabolic impact as markers associated with disease progression in type 1 diabetes 
patients at onset, at 12 and at 24 months after diagnosis, in high-risk subjects and 
in non-diabetic controls. A multiple correlation matrix among different parameters 
was evaluated statistically and assessed visually on two-dimensional graphs. The 
meta-immunological profile changed significantly among the three studied groups 
and in patients over time, and a specific signature that associated with worsening 
disease was identified. Finally, markers to predict residual β-cell function up to 
one year after diagnosis were identified in a multivariate logistic regression model. 
This latter model, measuring age, body mass index (BMI), fasting C-peptide (C-
pep), number of circulating CD3
+
CD16
+
CD56
+
 cells and percentage of 
CD1c
+
CD19
-
CD14
-
CD303
-
 type 1 myeloid dendritic cells (mDC1s) at disease 
onset had a significant predictive value. The identification of a specific meta-
immunological profile associated to disease status may contribute to understand 
the basis of diabetes and its progression, and provide novel biomarkers that could 
help clinicians in disease monitoring and in the choose of the most appropriate 
therapeutic approach according to disease status and aggressiveness. 
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1. Background 
 
 
1.1 Epidemiology of type 1 diabetes: urgency for prevention 
 
Type 1 Diabetes (T1D) is an autoimmune disease characterized by a T cell-
mediated specific destruction of insulin-secreting pancreatic β-cells in genetically 
susceptible individuals.  
T1D is one of the most common and serious chronic diseases in children. 
Incidence varies greatly between different countries, within countries, and between 
different ethnic populations. Annual incidence rates for childhood T1D show the 
highest incidence of 64 per 100,000/year in Finland (Harjutsalo et al. 2008). 
Incidence in Italy is characterized by a large variability, from geographical areas 
with very high levels of incidence, as in Sardegna (36.9 per 100,000/year), to areas 
with intermediate levels of incidence, as peninsular areas (8.4 per 100,000/year). 
Moreover, data from the "Registry for Type 1 Diabetes Mellitus in Italy (RIDI)" 
Study Group report significant higher incidence rate in boys than in girls in 
Sardegna (particularly in the age-group 10-14 years), while few differences 
between sexes have been observed in peninsular regions. Finally, it is interesting 
to observe that T1D incidence has showed wide variations not only between 
Sardegna and mainland Italy, but also among the peninsular regions. Indeed, 
incidence rates of 11.2 in North Italy, 9.3 in Central Italy, and 6.2 in South Italy 
have been reported (Carle et al. 2004). A seasonal variation in the presentation of 
new cases is well described, with the peak being in the winter months. 
Over the past 60 years, the incidence of T1D worldwide has been increasing by 3-
5% per year (Figure 1), doubling approximately every 20 years.  
A recent report from Finland, which has the highest incidence in the world, 
suggested that the incidence is also increasing faster than before (Harjutsalo et al. 
2008). The rising incidence of T1D has been accompanied by a disproportionately 
greater increase in children under the age of 5 years (DIAMOND Project Group 
2006; Vehik et al. 2007; Patterson et al. 2012). A recently published review 
reported an overall annual increase of 3.9% in the incidence of childhood T1D in 
Europe and predicted that the incidence rate in children aged < 5 years will double 
between 2005 and 2020 (Patterson et al. 2009). 
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Figure 1. T1D incidence has doubled every 20 years. Data for Finland are from the Finnish 
National Public Health Institute (Harjutsalo V.); data for Sweden are from the Swedish Childhood 
Diabetes Registry; data for Germany are a compilation of two reports; data for Colorado are from 
the Colorado IDDM Registry, the Barbara Davis Center for Childhood Diabetes, and SEARCH for 
Diabetes in Youth. 
 
 
The rising incidence and earlier age of onset of pediatric T1D increase the urgency 
for its prevention and for interventions able to preserve functional β-cell mass.  
The goals of a successful prevention approach in T1D should be cessation of β-cell 
destruction, reversal of autoimmunity and preservation of surviving β-cells in 
order to allow any natural regenerative potential to be realized. In addition, 
prevention interventions should realize these goals with a minimal degree of 
interference with the general functions of the immune system in order to avoid 
severe disturbances of immune surveillance mechanisms leading to intolerable 
side effects.  
To this aim, biomarkers to stage and predict progression of the disease are needed 
and a more detailed understanding of disease mechanisms is required in order to 
efficiently curb islet autoimmunity and ultimately design appropriate cures. 
 7 
 
1.2 Natural history of type 1 diabetes: genetic and environmental factors 
influencing the development of islet autoimmunity 
 
The model of the natural history of T1D suggests stages that commence with a 
genetic susceptibility, autoimmunity without clinical disease, and finally clinical 
diabetes (Figure 2) (Eisenbarth 1986). 
 
 
 
 
Figure 2. Natural history of type 1 diabetes (from Eisenbarth GS, 1986). 
 
 
Genetic susceptibility to autoimmune T1D is well documented and associated with 
multiple genetic loci. The human leukocyte antigen (HLA) class II region on the 
short arm of chromosome 6 confers approximately half of the genetic risk of T1D. 
In addition, several non-HLA susceptibility genes have also been identified, 
mostly supporting a dominant role for an immune-mediated pathogenesis (Steck et 
al. 2005). Among HLA susceptibility genes, markers conferring increased risk 
include: HLA DRB1*03 - DQA1*0501 - DQB1* 0201 and HLA DRB1*04 - 
DQA1*0301 - DQB1* 0302 (Erlich et al. 2008). Of note, several recent studies 
have shown that there has been a decrease over time in the proportion of the high-
risk HLA genotype, with an increase in low- to moderate-risk genotypes among 
type 1 diabetes patients in Finland (Hermann et al. 2003), UK (Gillespie et al. 
2004), Colorado (Vehik et al. 2008), Australia (Fourlanos et al. 2008) and in 
Sweden (Resic-Lindehammer et al. 2008). 
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The presence of a genetic susceptibility, however, is not a sufficient condition for 
the development of islet autoimmunity and type 1 diabetes. Several environmental 
factors have been suggested to act as a trigger for autoimmunity and influence 
progression to clinical diabetes, in genetic susceptible individuals (Figure 3). 
Furthermore, the rapid increase in T1D incidence observed in the latest decades, 
together with the spreading to children bearing moderate- to low-risk HLA 
genotypes, strongly suggests an increased environmental pressure and a powerful 
influence of the environment interacting with the genetic background. The 
increased incidence in the very youngest children strongly suggests a role for early 
environmental exposures, as well. 
 
 
 
 
 
Figure 3. Environmental triggers influence the development of islet autoimmunity and  progression 
to clinical diabetes 
 
 
The development of an autoimmune process against Langerhans islets is 
characterized by the appearance of islet autoantibodies, which can be measured in 
the serum of these subjects. Islet autoantibodies identified so far include 
autoantibodies against insulin (IAAs), the 65-kDa isoform of GAD (GADA), the 
protein tyrosine phosphatase-related molecule IA-2 (IA-2A), and more recently 
autoantibodies against the pancreatic β-cell specific protein, zinc transporter 8 
(ZnT8). Once islet autoantibodies have developed, the progression to overt 
diabetes in autoantibody-positive individuals is determined by the age of antibody 
appearance and by the magnitude of the autoimmunity, in turn related to the age of 
the subject (Achenbach et al. 2005). The period preceding the clinical onset of 
T1D, called "pre-diabetes", is usually asymptomatic or characterized by subtle 
metabolic disturbances. When most of the β-cell mass is lost, clinical signs of 
chronic hyperglycemia become evident and consequently patients need frequent 
blood glucose testing and daily insulin replacement therapy. 
Over the last 20 years, several groups have carried out prospective studies from 
birth (BABYDIAB, Finnish DIPP, DAISY, TEDDY) that investigated the 
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development of islet autoimmunity and diabetes (Hummel and Ziegler 2011; 
Ziegler and Bonifacio 2012; Kimpimaki et al. 2001; Stene et al. 2004;  Snell-
Bergeon et al. 2012; TEDDY Study Group 2008). Such studies have shown that 
islet autoimmunity usually occurs very early in life. Indeed, the majority of 
children developing T1D in early childhood (< 10 years of age) have the first signs 
of islet autoimmunity by 2 years of age (Ziegler and Bonifacio 2012). Children 
who develop autoantibodies within the first 2 years of life are those who most 
often develop multiple islet autoantibodies and progress to type 1 diabetes in 
childhood. Autoantibodies do not exclusively develop before age 2 years, but 
children who develop autoantibodies later have a slower progression to multiple 
autoantibodies and type 1 diabetes (Hummel et al. 2004). 
Environmental factors that have been proposed to contribute to islet autoimmunity 
and T1D risk include exposures taking place during pregnancy, infancy, 
childhood, and beyond. Several gestational factors are considered to increase the 
risk for T1D in childhood, although there is a gap in understanding to what extent 
gestational factors may trigger islet autoimmunity or merely increase T1D 
susceptibility in the offspring. Potential gestational risk factors include exposure to 
rubella during pregnancy (Menser et al. 1978), mother's enterovirus infections 
during pregnancy (Hyoty et al. 1995), and high birth weight for gestational age 
(Stene et al. 2004).  
Candidate risk factors operating during infancy include those related to exposure 
to infectious agents, improved hygiene and mucosal exposure to dietary 
constituents. Enteroviruses, particularly coxsackie B viruses, are currently 
considered as the prime candidate among infectious agents by nature of their 
tropism for β-cells, possible molecular mimicry, and early and more recent reports 
of their presence in β-cells of patients with T1D (Yeung et al. 2011; Atkinson et al. 
1994; Dotta et al. 2007; Yoon et al. 1979). 
Seemingly in contrast to the infectious hypotheses is the notion that improved 
hygiene is responsible for upward trends in T1D incidence (Gale 2002). Few 
studies have examined the relationship between hygiene and development of islet 
autoimmunity. Related to hygiene is a potential role of vaccinations in the 
development of islet autoantibodies or progression to T1D. Some have suggested 
that vaccinations increase T1D risk, but well-designed studies have found no 
evidence for this (Graves et al. 1999; De Stefano et al. 2001). The temporal 
relationship of vaccinations to the development of islet autoantibodies or T1D has 
never been examined. Prospective analyses of children from 3 months of age 
through the entire period of mandatory or voluntary vaccinations are needed to 
establish effects of vaccinations on islet autoimmunity and progression to T1D 
(TEDDY Study Group 2008). 
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Several studies are also exploring the hypothesis that alterations in the intestinal 
microbiota in early childhood could increase susceptibility to the development of 
T1D (Hara et al. 2013; Hummel and Ziegler 2011; Norris et al. 2003). 
Overall, several environmental factors seem to modify the risk of islet 
autoimmunity and T1D and have been considered to trigger autoimmune responses 
against pancreatic β-cells, eventually leading to β-cell destruction. The 
heterogeneity of T1D progression and clinical manifestations is likely a reflection 
of this complex multifactorial pathogenesis. Among environmental factors, several 
evidence points to infectious agents, components of early childhood diet and gut 
microbioma. However, besides the “classical” triggers (infections, diet, gut), 
growing evidence points at inflammation and metabolic changes as significant 
cofactors in T1D pathogenesis. These could even precede the triggering of islet 
autoimmunity, and may promote chronic immune dysregulation through effects on 
both innate and adaptive immune responses. Inflammation and insulin resistance 
are emerging as additional cofactors, which might be interrelated with the other 
known environmental factors. Secular trends in increased BMI and sedentary life 
style have been thought to contribute to the increased spreading of autoimmune 
type 1 diabetes (Knip et al. 2008). Obesity, insulin-resistance, or both have been 
suggested as important risk factors for type 1 diabetes (Hypponen et al. 2000; 
Rosenbloom 2003; Wilkin 2008). 
There are several possible mechanisms to explain the increased risk of type 1 
diabetes with increasing BMI in children. Fat cells secrete adipokines and 
cytokines, which may affect not only β-cell function, but also either increase the 
risk for or accelerate islet autoimmunity by influencing deleterious or protective 
local immune responses occurring in the pancreas. Furthermore, overweight 
increases insulin-resistance and the combination between islet autoimmunity and a 
demand for more insulin with increasing BMI may lead to an exhaustion of β-
cells.  
Overall, environmental triggers that contribute to the initiation and progression of 
pancreatic β-cell destruction still remain largely unknown. However, it is well 
documented that the "pre-diabetic" phase can last from months to years before the 
manifestation of clinical symptoms. In addition, at the time of clinical onset, the 
remaining portion of β-cell mass, although small (about 15-20% of the original β-
cell mass), still has noticeable benefits. For these reasons, many efforts are being 
reserving to the identification of new immune therapies able to prevent the clinical 
onset in subjects with islet autoantibodies and/or preserve residual β-cell function 
in patients newly diagnosed with type 1 diabetes. Clinical immune interventions 
thus far have been mostly ineffective in delaying progression to overt diabetes in 
relatives at increased risk, or in reducing further loss of insulin secretion and 
producing lasting remission in patients with new-onset diabetes. This limited 
success may reflect our incomplete understanding of key pathogenic mechanisms, 
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the lack of truly robust biomarkers of both disease activity and β-cell destruction 
and the inability to assess the relative contributions of various pathogenic 
mechanisms at various time points during the course of the natural history of T1D. 
One of the most important current limitation to T1D immunotherapy is the lack of 
suitable biomarkers of the successive phases of disease.  
Finally, the process of β-cell destruction is believed to be non-linear (von Herrath 
et al. 2007). In addition, 43-56% of children with T1D experience a honeymoon-
phase, characterized by a temporary amelioration of β-cell function, which can last 
up to 24 months or even longer (Buyukgebiz et al. 2001). Both non-linear β-cell 
destruction and the honeymoon-phase suggest that the nature of the immune 
response towards β-cells potentially changes over time, yet the exact kinetics for 
these processes are unknown. It is also possible, that in humans β-cell loss is a 
relapsing syndrome, in which possible subsiding immune attack periods separate 
the infiltration of different lobes of the pancreas. Hence, immunotherapeutic 
approaches should ideally be tailored to the status of an individual’s disease, 
specifically his/her β-cell mass. However, one of the current limitations to such an 
approach is the lack of biomarkers available to assess the existing β-cell mass and 
immunoreactivities to β-cell antigens precisely, this being particularly important 
before exposing very young patients and/or pre-diabetic (clinically healthy) 
individuals to reagents developed to interfere with their immune system. 
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1.3 Pathogenesis of type 1 diabetes: immune mechanisms underlying the 
selective destruction of pancreatic β-cells 
 
Insulin-secreting β-cells are localized in the islets of Langerhans, scattered 
throughout the exocrine portion of the pancreas. Methodological options in 
studying immune responses leading to human T1D are extremely limited by the 
localization of the pancreas deep inside the abdominal cavity.  Therefore, tissue 
sampling from T1D subjects is currently restricted to peripheral blood. As a 
consequence, one of the current limitation to the comprehension of T1D 
pathogenesis is undoubtedly that our hypotheses are usually built on the premise 
that cell populations found in the blood at least to some extent mirror the ones that 
infiltrate the islets.  
Studies in animal models, particularly in non-obese diabetic (NOD) mice, have 
identified roles for several different immune cell types in β-cell destruction. CD4+ 
and CD8
+
 T cells, as well as macrophages, have been shown to have a role in β-
cell death. However, other cell types are present in the pancreatic infiltrate and in 
the pancreatic draining lymph node, where the initial presentation of islet antigen 
by dendritic cells (DCs) to islet antigen-specific T cells occurs. These cells include 
B cells, Natural Killer (NK) cells and NKT cells, as well as DC subsets, and they 
could also contribute to β-cell death. This strongly suggests that there is substantial 
crosstalk between the immune cells that are involved in pathogenesis and those 
involved in immune regulation (Lehuen et al. 2010). Moreover, pro-inflammatory 
cytokines secreted by local antigen-presenting cells (APCs), NK cells, and T-cells 
contribute to further recruitment and activation of immune cells, consequently 
enforcing this autoimmune assault on the β-cells. 
An overview of the disease mechanisms that are thought to be involved at various 
stages of human T1D development is provided by the Figure 4. 
In response to an environmental trigger, β-cells produce inflammatory mediators 
such as interferon (IFN)-alpha and up-regulate their surface expression of MHC 
class I. Under such conditions of stress, β-cell antigens are released and taken up 
by antigen-presenting cells, such as dendritic cells and macrophages. The APCs 
migrate to the pancreatic draining lymph nodes and present β-cell auto-antigens to 
both Th1 cells and T-regs, with a critical role for TNF-alpha in generation of T-
regs. In normal individuals, T-reg cells inhibit the action of Th1 cells via cytokines 
such as IL-10. In susceptible individuals, however, a detrimental Th1 response and 
interferon (IFN)-gamma production is initiated, leading to B cell activation and 
autoantibody production. Together with direct recognition and killing of β-cells by 
cytotoxic T lymphocytes (CTLs), these effector mechanisms ultimately lead to β-
cell death and insulin deficiency (Coppieters et al. 2011). 
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Figure 4. Overview of the disease mechanisms involved in the pathogenesis of T1D. 
 
 
It is hypothesized that, during the pre-diabetic phase, a variable interplay between 
destructive and regulatory immune responses can occur and ultimately the 
destruction overtakes any attempts of the β-cells make to regenerate or proliferate. 
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1.4 Lymphocytes and type 1 diabetes 
 
There is considerable evidence that T cells have an important role in the 
development and progression of T1D in both humans and animal models. 
Studies in NOD mice have shown that T1D development depends on both CD4
+
 
and CD8
+
 T cells (Phillips et al. 2009). There are several ways in which T cell-
mediated β-cell death might occur. Indeed, CD8+ T cells could kill pancreatic β-
cells through MHC class I-mediated cytotoxicity, and both CD4
+
 and CD8
+
 T cells 
produce cytokines, such as interferon-γ (IFN-γ), that induce expression of the 
death receptor FAS and chemokine production by β-cells. Activation of FAS by 
FAS ligand (FAS-L)-expressing activated T cells could initiate β-cell apoptosis. 
Chemokine production by β-cells results in further recruitment of mononuclear 
cells to the site, thereby enhancing inflammation (Eizirik et al. 2009). In addition, 
IFN-γ can activate macrophages and induce increased pro-inflammatory cytokine 
production, including interleukin-1β (IL-1β) and tumor necrosis factor (TNF). β-
cells express high levels of IL-1 receptor and seem to be more sensitive to IL-1β-
induced apoptosis than other endocrine cells in the islet. This crosstalk between T 
cells and macrophages undoubtedly exacerbates the immune-mediated stress on β-
cells and contributes to their destruction. 
Although T cells have a pathological role in T1D development, there is also 
evidence supporting a role for T cells in the prevention of β-cell destruction. 
Indeed, islet antigen-specific T cells can differentiate into either pathogenic 
effector T cells (diabetogenic T cells) or protective T-reg cells. T-regs seem to 
play an important role in preventing the onset of autoimmune disease, including 
T1D (Wildin and Freitas 2005).  
In conclusion, T cells are clearly pivotal for T1D development. However, there are 
also data suggesting an involvement of other cell types such as B cells. Indeed, It 
has been hypothesized a role for B cells as antigen-presenting cells that maintain 
islet antigen-specific T cell activity (Lehuen et al. 2010). 
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1.5 Innate immune cells in type 1 diabetes 
 
Although the importance of T cells in T1D pathogenesis has been largely 
elucidated, there is increasing evidence that innate immune cells have crucial roles 
in T1D pathogenesis. Macrophages, DCs and NK cells are required for the 
development of T1D in various mouse models and have been detected in the 
pancreas of patients with T1D (Uno et al. 2007). Several studies support a 
pathogenic role for macrophages in both the initiation and destruction phases of 
T1D. Recruitment of macrophages to islets is mediated by the secretion of 
chemokines by CD4
+
 T cells and pancreatic β-cells. Macrophages recruited to the 
pancreas produce IL-1β and TNF that can cause β-cell death (Yang 2008). NK 
cells are also involved in T1D pathogenesis. Several reports have described a 
correlation between the frequency and/or activation of NK cells with the 
destructiveness of the pancreatic infiltrate. NK cells are both cytotoxic and 
producers of cytokines, particularly IFN-γ, so that they could contribute directly 
and indirectly to the destruction of β-cells (Dotta et al. 2007; Alba et al. 2008). 
However innate immune cells have shown an ambivalent behavior as they can also 
be involved in protection against the disease. In particular, dendritic cells are an 
heterogeneous group of innate effectors that serve two general functions in 
controlling T-cell immunity. First, they are professional antigen-presenting cells 
that process and present antigens  and are responsible for the activation of naive T 
cells. Second, they can critically influence the characteristics of the T-cell 
responses through the secretion of cytokines that condition the extracellular milieu 
and determine the nature of the T-cell response. Indeed, through the production of 
pro-inflammatory or suppressive cytokines, they can define the milieu in which 
islet antigen-specific T cells are activated, determining the type of immune 
response that ensues and whether a deleterious or protective local immune 
response occurs in the pancreas. These opposing functions, in inflammatory 
responses against microbs and in immune-tolerance to self-antigens, are governed 
by the maturation status and types of cytokines secreted by dendritic cells. Under 
non-inflammatory or homeostatic conditions, the majority of dendritic cells are 
found in an immature state. Immature dendritic cells presenting self-antigens fail 
to both stimulate T-cells and secrete cytokines. Under certain conditions, immature 
dendritic cells presenting self-antigens can be tolerogenic by inducing either a 
state of unresponsiveness or apoptosis in the autoreactive T-cells (Wallet et al. 
2005). Presumably, in normal conditions, immunogenic DCs provide active host 
defenses, while tolerogenic DCs guard against autoimmunity and control 
established immune reactions. In autoimmune diseases, there is strong evidence to 
support the idea that tolerance is overridden by the development of immunogenic 
DCs that favor autoimmune responses. 
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Three types of dendritic cells can be isolated from in human blood: CD1c
+
 
myeloid dendritic cells (mDC1s), CD141
+
 myeloid dendritic cells (mDC2s), and 
CD303
+ 
plasmacytoid dendritic cells (pDCs). 
Myeloid dendritic cells are considered as a sort of ”sentinels” of immunity, ideally 
positioned throughout the body gateways and equipped with unique properties to 
transport antigens from the periphery to lymphoid tissues. They are professional 
antigen-presenting cells transmitting incoming infectious signals to T cells, the key 
players of adaptive immunity. However, besides this essential immunostimulatory 
function, these cells may act as pivotal players in the peripheral tolerance network 
by active induction of T cells with immunosuppressive functions and regulation of 
T effector cell activity (Steinbrink et al. 2009). In the context of autoimmune 
diabetes, mDCs could capture self-antigens released after β-cell death in the 
pancreatic islets and present them to islet antigen-specific T cells in the pancreatic 
lymph nodes where the diabetogenic response is initiated (Marleau et al 2008).  
By contrast, pDCs have a decreased capacity to take up, process and present 
soluble antigens. They are rather known for their capacity to detect viral RNA or 
DNA through TLR7 and TLR9 and to respond by secreting large amounts of type I 
IFNs, Il-12 and pro-inflammatory chemokines (Lande and Gilliet 2010). A 
putative role for pDCs in the development of T1D is supported by observations in 
both human and mouse models that type I IFNs, which are usually produced by 
this cell type, can in some situations induce or enhance T1D.  
Several studies have investigated mDCs and pDCs compartments and functions in 
diabetic individuals, and controversy exists whether numerical and/or functional 
disturbances of circulating DCs are associated with the disease. Indeed, there have 
been apparently discrepant data regarding the frequency of DCs in the blood of 
patients with T1D, which may reflect differences in the time when the blood 
samples were taken. Interestingly, pDCs from early-diagnosed patients were 
shown to present immune complexes to T cells more efficiently than mDCs, 
suggesting a possible detrimental role of pDCs in T1D onset (Peng et al. 2003; 
Vuckovic et al. 2007; Chen et al. 2008; Allen et al. 2009).  
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1.6 Leptin as an immune-endocrine mediator 
 
Leptin is an hormone, mainly secreted by the adipose tissue, reflecting the amount 
of energy stored. It regulates the balance between food intake and energy 
expenditure, signaling to the brain the changes in stored energy. In addition, it has 
been shown to play an important role in the regulation of neuroendocrine function 
and energy homeostasis and other energy-demanding physiological processes, 
such as reproduction, hemopoiesis, and angiogenesis (Matarese et al. 2005).  
Although the most important role of leptin is to regulate body weight through the 
inhibition of food intake and stimulation of energy expenditure by increased 
thermogenesis, recent evidence has indicated that leptin also play a key role in the 
regulation of the immune system (La Cava and Matarese 2004). Indeed, leptin act 
also as a cytokine and has structural similarity to other cytokines, such as IL-6, IL-
12, granulocyte colony-stimulating factor (G-CSF). 
Leptin actions are mediated by the leptin receptor, a membrane-spanning 
glycoprotein, that belongs to the class I cytokine receptor family (including 
receptors for IL-6, IL-12), and exists in at least six alternatively spliced forms with 
cytoplasmic domains of different length. Short forms of the leptin receptor are 
expressed by several non-immune tissues and seem to mediate the transport and 
degradation of leptin. The long form is expressed by the hypothalamus in areas 
that are responsible for the secretion of neuropeptides and neurotransmitters that 
regulate appetite and body weight, but is also expressed by immune cells, 
supporting a role for leptin in immune system. In addition, a soluble form of leptin 
receptor, present in the peripheral blood, represents the main leptin binding 
activity in human blood and modulates the bioavailability of free leptin. 
Leptin affects both innate and adaptive immunity (Figure 5). In innate immunity, 
leptin seems to promote activation of and phagocytosis by 
monocytes/macrophages and their secretion of leukotriene B4 (LTB4), 
cyclooxygenase 2 (COX2), nitric oxide and pro-inflammatory cytokines.  
Moreover, leptin can induce chemotaxis of neutrophils and the release of oxygen 
radicals. Finally, leptin also affects NK cell development and activation both in 
vitro and in vivo. 
The effects of leptin on adaptive immune responses have been extensively 
investigated on human CD4
+
 T cells. Leptin has different effects on proliferation 
and cytokine production by human naive (CD45RA
+
) and memory (CD45RO
+
) 
CD4
+ 
T cells, both of which express leptin receptor. In particular, leptin promotes 
proliferation and IL-2 secretion by naive T cells, whereas it minimally affects the 
proliferation of memory cells, on which it promotes the switch towards Th1-cell 
responses. This process is then sustained by an autocrine loop of leptin secretion 
by Th1 cells. Furthermore, leptin increases the expression of adhesion molecules 
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by CD4
+
 T cells, which could then be responsible for the induction of clustering, 
activation and migration of immune cells to sites of inflammation. 
 
  
 
 
Figure 5: Schematic representation of the effects of leptin on both innate and adaptive immunity. 
 
 
Overall, leptin is an adipocyte-derived hormone/cytokine that links nutritional 
status with neuroendocrine and immune functions. Research on leptin has 
provided important insights into the intricate network that links nutrition, 
metabolism and immune homeostasis. 
Altered serum levels of leptin have been reported in several chronic inflammatory 
conditions, such as pelvic endometriosis, nonalcoholic hepatitis, chronic 
pulmonary inflammation, IBD, inflammatory nephritis, Behcet’s syndrome, 
Graves' disease, T1D and rheumatoid arthritis (La Cava and Matarese 2004). 
Moreover, it is common to find an increase of leptin concentrations in the early 
phases of autoimmune diseases and before relapses (La Cava and Matarese 2004). 
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Of note, sampling and disease staging must be carefully evaluated when 
interpreting the results of these studies.  
The role in autoimmunity could be mediated by leptin produced by adipocytes 
present in the perilymphonodal adipose tissue and in the lymph nodes. In this 
context, leptin could promote the differentiation of T helper 1 (Th1) cells, the 
activation of monocytes/macrophages and the secretion of cytokines of the acute-
phase response and oxygen radicals. Autoantigens could be presented to Th0 cells 
that express the long form of the leptin receptor. Leptin could then affect the 
priming of autoreactive T cells towards Th1-type pro-inflammatory responses. 
Paracrine effects of Th1 cells that produce leptin after activation with antigen 
could then sustain an autocrine loop of proliferation and T-cell survival. 
The role of leptin in autoimmune diabetes has mainly been investigated in animal 
models. Serum levels of leptin increases in non-obese diabetic (NOD) mice before 
the onset of hyperglycemia and diabetes. In addition, intraperitoneal injection of 
leptin accelerates autoimmune destruction of insulin-producing β-cells in NOD 
mice (Matarese et al. 2002). Leptin has pro-inflammatory properties and could 
aggravate the development of Th1-dependent autoimmune diseases.  
Several evidence suggests the influence of metabolic factors on the development 
of autoimmunity and type 1 diabetes. Indeed, in the past decades we have 
witnessed a dramatic obesity epidemic, affecting not only adults but also pediatric 
population. Several studies report a dramatic increase in the prevalence of 
childhood overweight and obesity in recent decades (Wang and Lobstein 2006; de 
Onis et al. 2010). Such raising trend has been paralleled by a similarly dramatic 
increase in the incidence of type 1 diabetes. This increased incidence appears not 
to be uniformly distributed: T1D associated with high-risk HLA alleles has 
remained stable, whereas that associated with low-risk genotypes has increased 
significantly and a tendency to associate with obesity and insulin resistance has 
been observed (Carlsson et al. 2012). In addition, cohort studies have shown that 
children who develop type 1 diabetes were heavier in the first year of life as 
compared to their peers who remain free of disease, and that an increasing body 
mass index (BMI) strongly correlated with an earlier disease presentation 
(Hyppönen et al. 1999; Betts et al. 2005). Also, insulin-resistance related to 
overweight not only often preceded clinical onset, but was also the strongest 
predictor of type 1 diabetes, aside from HLA genotype (Fourlanos et al. 2008; 
Wilkin TJ 2008). 
In conclusion, increasing evidence is revealing the importance of several 
molecules, including leptin, operating at the interface between metabolism and 
immune responses (Odegaard and Chawla 2012). However, the intimate 
connection between molecules that influence body weight and the network of 
molecules, cells and pathways that finely tune the immune response makes these 
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studies complex. There is therefore still much to learn about the interaction 
between metabolism and immune responses.  
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2. Aim of the study 
 
 
The development of type 1 diabetes involves a complex interaction between 
pancreatic β-cells and both arms of the innate and adaptive immune system, which 
undoubtedly changes during the progression of the disease. In addition, several 
evidence is suggesting an important role for molecules operating at the interface 
between metabolism and immune responses in the development and progression of 
autoimmune diseases, such as type 1 diabetes. Meta-immunology has been 
developing over the last 10 years, and it can be used in the study of type 1 
diabetes, i.e. to link metabolism with immunity including immune tolerance. 
Altered functions, an imbalance of immune cell subsets, or both, and 
metabolic/inflammatory molecules may contribute to the initiation and progression 
of the β-cell autoimmune responses resulting in the clinical onset of the disease. 
In this study, we aimed at analyzing the meta-immunologic profile of newly 
diagnosed type 1 diabetes children, high-risk children and non-diabetic controls, 
and comparing the three studied groups in order to identify immune and/or 
metabolic markers specific of different stages of disease progression.  
Most of the studies that have examined meta-immunologic parameters in type 1 
diabetes had discrepant results, and did not yield definitive conclusions (Peng et 
al. 2003; Vuckovic et al. 2007; Chen et al. 2008; Allen et al. 2009). Moreover, 
they typically involved relatively small numbers of subjects and analyzed single 
(or a few) parameters (Schloot et al. 2007; Pfleger et al. 2008). More important, 
no study so far has examined meta-immunologic parameters for the prediction of 
residual β-cell function over time, e.g. via the monitoring of metabolic and 
immunologic functions characterizing type 1 diabetes. 
Therefore, we then examined all immune and metabolic parameters in order to 
find one or more immune/metabolic marker able to predict, since the time of 
disease onset, the residual β-cell function over time.  
Our approach tried to provide a way for discriminating, at disease diagnosis, 
children who will maintain a good β-cell function from those losing their function 
up to one year from diagnosis. 
 
 
During my PhD course, I also collaborated to other scientific studies in the field of 
pediatric diabetes. Such studies resulted in publications that are attached as PDF-
file at the end of the present manuscript. 
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3. Research, design and methods 
 
 
3.1 Subjects 
 
Children (n = 114, Table 1) receiving the diagnosis of type 1 diabetes were 
recruited after glycemic stabilization on exogenous insulin, achieved in 5 days.  
Diabetes was defined according to the Global IDF/ISPAD Guidelines for Diabetes 
in Childhood and Adolescence, and included symptoms of diabetes in addition to 
casual plasma glucose concentration ≥11.1 mmol/l (200 mg/dl), or fasting plasma 
glucose ≥7.0 mmol/l (≥126 mg/dl), or 2 hour post-load glucose ≥ 11.1 mmol/l 
(≥200 mg/dl) during an Oral Glucose Tolerance Test (OGTT), and Glycated 
Haemoglobin (HbA1c) ≥6.5 (IDF/ISPAD 2011 Global Guideline for Diabetes in 
Childhood and Adolescence). Among the 114 diabetic children, 40 had 
ketoacidosis at disease onset and 25 had at least another autoimmune disorder 
besides autoimmune diabetes, more frequently celiac disease (n = 12) or 
autoimmune thyroiditis (n = 13). 
 
Table 1 . Baseline characteristics of controls, high-risk subjects and diabetic patients at disease 
onset. 
 
 
 
Data are expressed as mean ± SD (Range); Body mass index (BMI) is the weight in kilograms divided by the 
square of the height in meters. † AIT: Autoimmune Thyroiditis; †† CD: Celiac Disease. 
 
 
Thirty-four healthy controls (n = 34, Table 1) were selected on the basis of the 
following criteria: fasting blood glucose of <5.5 mmol/L (<100 mg/dl), negative 
personal and familial history of autoimmune disorders and negativity for islet 
autoantibodies at the 99th percentile. Both diabetic children and control subjects 
were recruited in Department of Pediatrics at the University of Naples Federico II. 
A local Ethical Committee approved the study and parents gave informed consent. 
The third group designed as "high-risk" subjects included 29 individuals recruited 
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from baseline of the Diabetes Prevention - Immune Tolerance study at the Skåne 
University Hospital, Malmö, Sweden. Children carrying HLA susceptibility alleles 
for type 1 diabetes were defined as high-risk based on the presence of GAD65 
autoantibodies (GADA) and at least one more islets-specific autoantibodies (IA-
2A, ZnT8A or IAA). The Lund Regional Ethics Board approved the study and 
informed consent was obtained from all subjects or their parents in accordance to 
the Declaration of Helsinki. There was no significant difference among the three 
study groups concerning to gender and BMI Standard Deviation Score (BMI-
SDS). High-risk subjects were younger and consequently with lower BMI than 
controls and diabetics at onset. Characteristics of the study subjects are 
summarized in Table 1. 
 
 
3.2 Study design 
 
At the beginning of the study, children from each group were analyzed for a wide 
range of immune (Table 2) and metabolic parameters (Table 3). Diabetic children 
were followed for a period of twelve (n = 60) to twenty-four (n = 30) months after 
disease onset and were then analyzed for the same parameters measured at the 
diagnosis. In addition, patients were dichotomized into two different groups on the 
basis of residual fasting C-peptide (C-pep) evaluated one year later upon disease 
diagnosis. Specifically, diabetic children with C-pep <0.5 ng/ml were designed as 
“severe disease patients”, while patients with C-pep levels >0.5 ng/ml were 
defined “mild disease patients”. 
A multivariate logistic regression analysis was performed to identify, at the time of 
diagnosis, biological parameters predictive of a maintained pancreatic function 12 
months later. To exclude the possible influence of glucose levels on metabolic 
parameters, blood was drawn when glicemic values were into the range of 80-180 
mg/dl (4.4–10 mmol/L). The actual glucose levels at the time of draw were not 
considered in the analysis. 
 
 
3.3 Flow cytometry 
 
Immune cell profiling of all subjects of the three studied groups was done at the 
time of blood drawing. Prior to flow cytometry for lymphocyte subsetting, whole 
blood cells were analysed with a clinical-grade hematocytometer to determine 
absolute lymphocyte numbers in each sample. For the controls and type 1 diabetes 
patients, 100 µl of blood was incubated 30’ at room temperature with the specific 
antibodies combinations. Red blood cells were lysed using BD FACS lysing 
Solution 2 (BD Bioscience) for 10’ and samples subsequently washed and 
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resuspended in 300 µl phosphate buffered saline (PBS). Flow cytometry was 
carried on cells gated on CD45
+
 - Side Scatter (SSC). Immunophenotypic analysis 
was performed with an EPICS XL flow cytometer (Beckman Coulter, Milan, Italy) 
using the Beckman Coulter software program XL System II. Triple combinations 
of different human mAbs, e.g., FITC- and phycoerythrin (PE)-anti-CD3, PE- and 
PC-5-anti-CD4, PC5-anti-CD8, PE-anti-CD16, PC5-anti-CD19, PE-anti-CD25, 
FITC-anti-CD45, and PE-anti-CD56 (all from Coulter Immunotech, Marseille, 
France) were used to identify different cell populations. For high-risk subjects, 
whole blood samples were stained with the following monoclonal anti-human 
antibodies in various combinations for flow cytometry: fluorescein isothiocyanate 
(FITC)-conjugated CD3; phycoerythrin (PE)-conjugated CD19 and CD8; peridinin 
chlorophyll protein (PerCP)-conjugated CD4; CD16 and CD56 (PE) (all from BD 
Bioscience, Becton, Dickinson, Franklin Lakes, NJ, USA). Briefly, 100 µl of 
blood was used for each staining, and samples were incubated 20-30 min. at room 
temperature. Red blood cells were lysed using BD FACS lysing Solution 2 and 
samples were washed and resuspended in 300 µl in FACS buffer for flow 
cytometry. Lymphocytes cell analysis was done on gated CD45
+
 - Side Scatter 
(SSC) cells with a FACSCalibur (BD, Bioscience, NJ, USA). Data were analysed 
using CellQuest software (Becton Dickinson). No differences in the analysis of 
three studied groups can be ascribed to procedures employed, since the same 
clones of monoclonal antibodies and similar experimental conditions were used in 
the flow cytometry setting. 
Circulating myeloid (mDCs) and plasmacytoid (pDCs) dendritic cells were 
evaluated using the Blood Dendritic Cells Enumeration Kit (Miltenyi Biotec, 
Germany). Specifically, mDC1s, mDC2s and pDCs were identified based on the 
expression of CD1c, CD141 and CD303 markers, after exclusion in the analysis of 
the CD19
+
 and CD14
+
 cells. The samples were analyzed by a CyAn flow 
cytometer and Summit software (Instrumentation Laboratory, Massachusetts, 
USA). Cell numbers are expressed as percent of a given cell population multiplied 
by number of lymphocytes/100, except for the number of DCs for which the 
percentage is referred to white blood cells (WBCs). 
 
 
3.4 Laboratory tests 
 
For controls and high-risk subjects, a 4 ml blood sample was obtained at the time 
of recruitment. For patients, a 4 ml blood sample was obtained at diabetes onset 
and after 12 and at 24 months. An aliquot from each blood sample was used to 
perform immune cell profiling by flow cytometry, and the remaining part of the 
sample was used for serum-based assays. Sera were centrifuged and kept at –80 °C 
until use. Fasting C-peptide levels were measured in duplicate serum samples, at 
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the same time in all samples, using a commercial ELISA kit (Millipore 
Corporation, Billerica, MA, USA). Results for each assay were validated and a 
high-level and a low-level control sample were included. 
Circulating leptin (Lep) and soluble leptin receptor (sLepR) were determined in 
duplicate serum samples using human Leptin and human Leptin sR 
Immunoassays, respectively (R&D System, Inc. Minneapolis, MN, USA). 
Soluble CD40L (sCD40L), soluble ICAM-1 (sICAM-1), monocyte 
chemoattractant protein-1 (MCP-1), myeloperoxidase (MPO), osteoprotegerin 
(OPG), resistin and soluble TNF-R (sTNF-R) were analyzed using the bead-based 
analyte detection system Human Obesity 9plex kit (Bender MedSystem Inc, 
Burlingame, CA, USA) in duplicate serum samples. 
Plasma glucose levels were measured using enzymatic hexokinase method. HbA1c 
was measured by HPLC (HLC-723 G7 TOSOH, Bioscience, Tokyo, Japan). Islet 
autoantibodies (GADA, IA-2A and IAA) were measured by commercial ELISA 
(Pantec, Torino, Italy). 
 
 
3.5 Statistical Analysis 
 
Normally distributed continuous variables are reported as mean ± standard 
deviation; median (min - max) was used to describe not-normally distributed 
continuous variables; categorical variables are reported as number of occurrences 
and percentages. For all study variables, comparison among controls, high-risk 
subjects and patients was based on the non-parametric Kruskal-Wallis procedure 
followed by the Mann-Whitney U test with Bonferroni correction. Paired 
comparisons between patients at baseline and after 12 and 24 months from 
diagnosis were carried out using the Friedman test, followed by Wilcoxon signed-
rank test with Bonferroni correction. Spearman correlation coefficient was 
computed to investigate the biological correlations between the different variables. 
Due to the large number of the variables examined and to control the family-wise 
error rate at level α = 0.05, significance of Kruskall-Wallis, Friedman and 
Spearman correlation p values were judged by using the adaptive Bonferroni 
procedure (Guo et al. 2010; Guo 2009). 
A multivariable logistic regression model was fitted to predict the residual C-
peptide secretion (dichotomized as 1 if ≤ 0.5 ng/ml and 0 if > 0.5 ng/ml) after 12 
months from the diagnosis on the basis of patients’ baseline measurements. The 
following two steps model strategy was adopted. All variables reported in Table 2 
and Table 3 were tested in univariate analysis. Only the variables showing a 
univariate association with the outcome (p <0.25) were included in the subset of 
candidate predictors. Afterwards, a backward elimination procedure (with a 
probability for removal equal to 0.10) was applied to identify those variables 
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independently associated with the residual C-peptide. In this second step, the 
model was further adjusted for the following covariates measured at diagnosis: 
age, BMI and fasting C-peptide secretion (dichotomized as 1 if ≤0.5 ng/ml and 0 if 
>0.5 ng/ml). This full model, including variables independently associated with 
residual C-peptide, was compared with a base model including only the adjusting 
covariates (i.e. age, BMI and C-peptide secretion measured at diagnosis). 
Prognostic validity of the fitted models was evaluated by ROC curve analysis and 
measured using the area under the ROC curve (AUC). Comparison among 
different AUC ‘s was carried out using the non-parametric approach (De Long et 
al. 1988). For all analyses, we used two-sided tests, with p values <0.05 denoting 
statistical significance (unless otherwise specified). Modelling and statistical 
analyses were carried out using R version 2.12.1 and SPSS software version 16 for 
Mac (SPSS Inc, Chicago, IL, USA). 
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4. Results 
 
 
4.1 Meta-immunological profiling of type 1 diabetes patients at onset, high-risk 
subjects and controls 
 
To depict the immunological profile of type 1 diabetes at onset, we analyzed 
several immune cell populations in the peripheral blood of children at onset in 
comparison with high-risk subjects and controls (Table 2).  
 
Table 2. Absolute number and percentages of circulating immune cells in controls, high-risk 
subjects and diabetic patients at disease onset (percentages in brackets). 
 
 
Data are expressed as mean ± SD; * type 1 myeloid dendritic cells (mDC1s): CD1c+CD19-CD14-CD303- 
cells; ** type 2 myeloid dendritic cells (mDC2s): CD141+CD1c-CD19-CD14-CD303- cells; *** plasmacytoid 
dendritic cells (pDCs): CD303+CD1c-CD19-CD14- cells; § statistical significance between diabetic patients at 
onset and high-risk subjects (p < 0.0001); nd = not determined, ns = not significant.  
Absolute cell numbers and percentages (in brackets) of circulating immune cells in the three studied groups 
expressed as mean ± SD. The absolute number per mm3 of all cell populations was calculated as follows: 
percent of a given cell population multiplied by the number of lymphocytes/100, except for the number of 
dendritic cells for which the percentage was referred to white blood cells (WBCs). 
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We found that patients at onset had a significantly lower percentage of circulating 
CD8
+
 T cells as compared to high-risk subjects (p = 0.001, after Bonferroni 
correction) but not compared to healthy controls. Furthermore, diabetic children 
also showed a significant higher number of CD4
+
 T cells with a memory 
phenotype (CD4
+
CD45RO
+
) as compared to the controls (p = 0.03, after 
Bonferroni correction). Finally, patients had a significantly higher percentage (p = 
0.03, after Bonferroni correction) and total number (p = 0.01, after Bonferroni 
correction) of CD303
+
CD1c
-
CD19
-
CD14
-
 plasmacytoid dendritic cells (pDCs) 
compared to healthy subjects (Table 2). 
To characterize the meta-immunological profile of type 1 diabetes, several 
indicators of inflammatory and metabolic activities (leptin, sLepR, MCP-1, 
sCD40L, MPO, sICAM-1, resistin, OPG and sTNF-R) were analyzed (Table 3 and 
Figure 6). Diabetic children at onset had lower levels of circulating leptin (p 
<0.001, after Bonferroni correction) and higher concentrations of circulating 
sLepR compared to both high-risk (p <0.001, after Bonferroni correction) and 
control subjects (p <0.001, after Bonferroni correction). High-risk subjects showed 
intermediate levels of sLepR between controls and patients (p <0.001, after 
Bonferroni correction) (Table 3 and Figure 6).  
We also observed that circulating levels of the pro-inflammatory chemokine MCP-
1 were significantly higher in children affected by type 1 diabetes than in high-risk 
subjects (p <0.001, after Bonferroni correction) and significantly lower in high-
risk subjects as compared to controls (p <0.001, after Bonferroni correction). The 
same trend was observed for the circulating plasma levels of sCD40L (Table 3 and 
Figure 6). 
 
Table 3.  Serum levels of inflammatory/metabolic circulating factors in controls, high-risk subjects 
and diabetic patients at disease onset. 
 
Data are reported as median and range; ^ Statistical significance between diabetic patients at onset and 
controls (p < 0.0001); § Statistical significance between diabetic patients at onset and high-risk subjects (p < 
0.0001); † Statistical significance between high-risk subjects and controls (p < 0.0001); ns = not significant. 
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Figure 6. Meta-immunological profiling in patients at onset, in high-risk subjects, and in controls 
 
 
 
Box plots show the distribution of circulating level of leptin, sLepR, MCP-1 and sCD40L in type 1 diabetes at 
onset, high-risk subjects and controls. Dots represent outliers values, i.e. data points below Q1 - 1.5xIQR or 
above Q3 + 1.5xIQR while asterisks represent extreme values, i.e. data points below Q1 – 3xIQR or above Q3 
+ 3xIQR. Q1=25th percentile; Q3=75th percentile; IQR (Interquartile Range) = Q3-Q1. Data are shown as 
median (min-max). Patients had lower serum levels of Lep (p < 0.001) and higher serum levels of sLepR (p 
<0.001) than controls. High-risk subjects had intermediate levels of sLepR between children with type 1 
diabetes and controls. Both patients and controls had higher levels of MCP-1 than high-risk subjects; the same 
was observed for sCD40L levels. 
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4.2 Meta-immunological follow-up profiling of type 1 diabetes patients 
 
Sera from patients were also analyzed at follow-up, namely at 12 and 24 months 
after disease diagnosis. It was found that during disease progression there was a 
significant progressive reduction in the number of CD4
+
 T cells, with lowest 
values at 24 months after diagnosis (Figure 7). The same trend was observed for 
the absolute number of circulating CD19
+
 B cells. In addition, during disease 
progression, there was a progressive reduction in the absolute number of 
circulating T cells with a memory phenotype (CD4
+
CD45RO
+
 or CD3
+
CD45RO
+
). 
Conversely, the percentage of naïve T cells (CD3
+
CD45RA
+
) was lower at disease 
onset as compared to values observed at later time points. In addition, there were 
higher absolute numbers of NK cells (p = 0.002, after Bonferroni correction) and 
CD141
+
CD1c
-
CD19
-
CD14
-
CD303
-
 type 2 myeloid dendritic cells (mDC2s) at 12 
months compared with those observed at 24 months after disease onset (p = 0.006, 
after Bonferroni correction). The CD3
+
CD16
+
CD56
+
 cells subset was lower at 
onset as compared to later time points. In serum, a progressive decline of 
circulating sLepR levels at 12 and at 24 months (p < 0.001 for both, after 
Bonferroni correction) and a progressive reduction of circulating OPG were 
observed from disease onset thereafter (Figure 8).  
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Figure 7. Immunological profiling in the follow-up of T1D patients  
 
 
 
 
 
Children affected by type 1 diabetes were studied at diagnosis, 12 and 24 months after disease onset. Box 
plots show the distribution of  CD4+ T cells, CD19+ B cells, CD4+ CD45RO+ T cells, CD3+CD45RO+ T cells, 
CD3-CD16+CD56+ cells, CD141+ cells and percentages of CD3+CD45RO+ T cells,  CD3+CD16+CD56+ cells, 
and CD3+CD45RA+ T cells in patients at onset and after 12 and 24 months. 
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Figure 8. Metabolic profiling in the follow-up of T1D patients  
 
 
 
 
 
Children affected by type 1 diabetes were studied at diagnosis, 12 and 24 months after disease onset. Box 
plots show the distribution of  circulating levels  of sLepR and OPG, in diabetic children at onset, 12 and 24 
months later. Patients had very high circulating levels of sLepR at disease onset. Serum levels of sLepR 
showed a trend towards reduction over time, with lower serum levels after 24 months from disease onset (p < 
0.001). Serum levels of OPG pregressively decreased over time (p = 0.011). 
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4.3 Multiple correlations among meta-immunological markers 
 
We performed multiple correlation analyses in diabetic patients at onset, high-risk 
individuals, and controls. In the group affected by type 1 diabetes, sLepR inversely 
correlated with circulating levels of fasting C-pep (r = -0.39, p <0.001), which 
reflects β-cell function. This correlation was not present in controls or in high-risk 
subjects (Figure 9 and data not shown). Moreover, in patients at onset the 
circulating levels of resistin positively correlated with those of sTNFr (r = 0.47, p 
<0.001), MCP-1 (0.52 with p <0.001) and MPO (r = 0.71, p <0.001). Circulating 
MCP-1 positively correlated with MPO and sTNFr levels (r = 0.62, p <0.001 and r 
= 0.52 with p <0.001, respectively). All these correlations were not present in 
controls and in high-risk subjects (Figure 9 and data not shown). 
In terms of immune cell subsets, several correlations were only found in patients 
and not in controls and high-risk subjects. In particular only in the group of 
patients, the percentage of CD3
+
 cells inversely correlated with the percentage of 
NK (r = -0.41, p <0.001) and B cells (r = -0.65, p <0.001). Moreover, the NK cells 
inversely correlated with both CD3
+
CD45RA
+
 (r = -0.51, p <0.001) and 
CD4
+
CD45RA
+
 (r = -0.46, p <0.001) naïve T cells (Figure 9). 
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Figure 9. Multiple biological correlations in type 1 diabetes 
 
 
 
 
 
Two-dimensional graphical representation of the Spearman ρ non-parametric correlation matrix among the 
studied variables. The presence of a significant correlation between two variables is expressed by means of a 
red (negative correlation) or blue (positive correlation) ellipse, while an empty circle refers to a non-
significant correlation. The color intensity and thickness of each ellipse are proportional to the correlation 
value (see graphic legend for numeric values). Correlation analysis, performed on all parameters analyzed, 
revealed a distinctive immune/metabolic profile for controls and new onset diabetic patients. A negative 
correlation between sLepR and β-cell residual fasting C-pep secretion (r= -0.39, p <0.001) was observed in 
individuals affected by type 1 diabetes but not in controls. 
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4.4 One year follow-up 
 
Meta-immunological correlations in diabetic patients at onset and 12 months post 
diagnosis were also studied. Significant differences were observed as compared to 
the same patients at diabetes onset (Figure 10). For example, the inverse 
correlation between sLepR and fasting C-peptide observed at disease onset, was 
lost after 12 months. A series of positive correlations at diagnosis, such as resistin 
vs MCP-1 (r = 0.52, p <0.001) and MPO (r = 0.70, p <0.001) as well as MCP-1 vs 
MPO (r = 0.22, p <0.01) were observed. Only the correlation between resistin and 
MPO was maintained over time (r = 0.51, p <0.001) (Figure 10). At the cellular 
level, the correlations among percentage CD3
+
 T cells vs NK and B cells observed 
at diagnosis was lost after 12 months, whereas the percentage CD4
+
CD45RO
+
 T 
cells inversely correlated with that of CD3
+
CD45RA
+
 T cells and CD4
+
CD45RA
+
 
T cells at disease onset. These correlations were not maintained one year later 
(Figure 10). 
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Figure 10. Multiple biological correlations in type 1 diabetes children over time 
 
 
 
   
Two-dimensional graphical representation of the Spearman ρ non-parametric correlation matrix among the 
study variables. The presence of a significant correlation between two variables is expressed by means of a red 
(negative correlation) or blue (positive correlation) ellipse while an empty circle refers to a non-significant 
correlation. The color intensity and the thickness of each ellipse are proportional to the correlation value (see 
graphic legend for numeric values). Correlation analysis, performed on all parameters analyzed, revealed a 
distinctive immune/metabolic profile for children with type 1 diabetes over time. The inverse correlation 
between sLepR and fasting C-pep, observed at disease onset, was lost 12 months later. 
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4.5 A novel predictive tool of residual ß-cell function over time 
 
The possibility to predict residual C-peptide levels after disease onset and the 
identification of biomarkers assessing therapeutic efficacy is a major goal in type 1 
diabetes monitoring and prognosis. Multivariable logistic regression analysis 
showed that the number of CD3
+
CD16
+
CD56
+
 T cells and the percentage of 
CD1c
+
CD19
-
CD14
-
CD303
-
 type 1 myeloid dendritic cells (mDC1s) at disease 
diagnosis were independent predictors of low (≤0.5) residual C-peptide secretion 
after 12 months from diagnosis, after adjustment for age and BMI as covariates 
measured at diagnosis. The data in Table 4 report the regression coefficient, the 
corresponding O.R. and 95% C.I. for the model and for a reduced base model 
including only the adjusting factors. In addition, a linear regression model 
confirmed the predictive role of CD3
+
CD16
+
CD56
+
 T cells and CD1c
+
CD19
-
CD14
-
CD303
-
 type 1 myeloid dendritic cells (mDC1s) independently of age, BMI 
and C-peptide values at onset (data not shown). Figure 11 shows the ROC curves 
associated to the base model and to the full model. The AUC of the full model was 
0.936 (p <0.001) and, compared to the AUC of the base model (0.781, p <0.001), 
was significantly higher (p = 0.005). Box plots in Figure 11 indicate that low 
CD3
+
CD16
+
CD56
+
 T cells and low mDC1s at disease onset associated with a 
reduced β-cell activity (fasting C-pep ≤0.5 ng/dl) in type 1 diabetes one year later. 
To characterize further the patients with different residual β-cell function, we 
performed a correlation analysis of “severe disease patients” (fasting C-pep ≤0.5 
ng/dl) and “mild disease patients” (fasting C-pep >0.5 ng/dl) at disease onset and 
one year later. We observed that in patients with a worse pancreatic function 
(fasting C-pep ≤0.5 ng/dl), resistin positively correlated with the levels of C-pep, 
MCP-1 and sTNF-R. In addition, in this group there was also a positive correlation 
between MCP-1 and sTNF-R. These correlations were not observed in patients 
with residual β-cell function (fasting C-pep >0.5 ng/dl). An inverse correlation 
between the percentage of naïve T cells (CD4
+
CD45RA
+
) and memory T cells 
(CD4
+
CD45RO
+
) was observed in severe-disease patients, but not in mild-disease 
patients. Many of the correlations observed at diabetes onset were not present 12 
months after disease onset. CD3
+
 positively correlated with CD4
+
 (and 
CD4
+
CD28
+
) in severe-disease patients, but not in mild-disease patients. Only in 
mild-disease patients did we observe an inverse correlation between 
CD3
+
CD45RA
+
 and CD3
+
CD45RO
+
 (Figure 12). 
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Table 4. Estimated regression coefficients and adjusted odds ratio (with their 95% CI) for 
predictors of residual C-pep secretion in the base and in the full logistic regression model. 
 
 
 
 
Figure 11. Prediction analysis 
 
 
 
A) Receiving operating characteristics (ROC) curves of the model-based prognostic scores for residual ß-cell 
functioning. The base model included only age, BMI and fasting C-pep secretion measured at disease onset, 
while the full model added the number of CD3+CD16+CD56+ T cells and the percentages of mDCs to the base 
model.  
B) Dot plot showing that high numbers of CD3+CD16+CD56+ T cells at onset associated with a reduced β-cell 
activity one year later. Low numbers were associated to a residual β-cell function.  
C) Dot plot showing that the high percentage of mDCs at onset was associated to a reduced β-cell activity one 
year later. Conversely, low numbers of these cells associated with residual β-cell function. 
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Figure 12. Distinctive correlation profiles of patients affected by type 1 diabetes according to 
disease severity, at onset and 12 months later 
 
   
 
 
Graphical representation of the Spearman ρ non parametric correlation matrix among the study variables. The 
presence of a significant correlation between two variables is expressed by means of a red (negative 
correlation) or blue (positive correlation) ellipse while an empty circle refers to a non-significant correlation. 
The colour intensity and thickness of each ellipse are proportional to the correlation value (see graphic legend 
for numeric values). The correlation profile between patients with mild and severe disease at onset and 12 
months later is shown. 
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5. Discussion 
 
 
The comprehension of the pathogenesis of type 1 diabetes has improved 
considerably in recent years, yet there is a lack of predictive markers of risk for 
disease progression and pancreatic β-cell loss. Such markers could be very useful 
to monitor the disease, to evaluate therapeutic efficacy and to ameliorate 
prognosis. 
The meta-immunological profiling described here for type 1 diabetes at onset and 
during progression identified 3 circulating immune cell populations and 4 
metabolic/inflammatory markers as significantly different among diabetic patients 
at onset, in high-risk subjects and in controls. CD8
+
 T lymphocytes were 
significantly higher in high-risk subjects as compared to patients according with 
previous report (Pinkse et al. 2005), a finding that is reminiscent of the known 
increased proliferation of this cell subset during insulitis, before the onset of 
hyperglycemia and overt diabetes. Higher numbers of memory T cells in patients 
at onset as compared to controls were also found. Interestingly, in the 24-months 
follow-up there was a progressive decline in the number of memory T cells in 
diabetic patients, in accordance with the findings that GAD65-specific T cells in 
diabetic patients bear a memory phenotype whereas in healthy individuals they are 
naïve T cells (Oling et al. 2012). We hypothesize that the progressive decrease of 
memory T cells might be secondary to a gradual exhaustion of islet-specific T cell 
clones after initial epitope spreading. Moreover, plasmacytoid dendritic cells were 
higher in children with type 1 diabetes at onset as compared to healthy children. 
This aspect is interesting because in presence of β-cell-specific autoantibodies, 
pDCs process and present islet autoantigens to CD4
+
 T-cells to amplify and 
maintain T-cell responses favouring epitope spreading (Allen et al. 2009). 
Previous investigations studied the frequency of this cell subset with discrepant 
results, showing either a reduced pDCs number in the blood of patients as 
compared to healthy controls (Chen et al. 2008; Vuckovic et al. 2007; Hinkmann 
et al. 2008) or an increased frequency of pDCs at diagnosis of type 1 diabetes 
(Allen et al. 2009). These conflicting results could depend on the procedures for 
the analysis, the timing of sampling, and the size of the studied population. Our 
study is the first one analyzing pDCs longitudinally for 24 months on a large 
cohort of patients following disease diagnosis. 
Metabolically, the leptin/sLepR axis was altered in newly diagnosed diabetic 
children as compared to high-risk subjects and controls. Leptin profoundly affects 
metabolism and immune functions (La Cava and Matarese 2004), and promotes 
the development of type 1 diabetes in NOD mice (Naito et al. 2011). On the 
contrary, it has been reported that leptin improves insulin-deficient type 1 diabetes, 
reverting catabolism through the suppression of hyperglucagonemia, resembling 
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the anabolic action of insulin monotherapy, and normalizing HbA1c (Wang et al. 
2010).  
Soluble leptin receptor (sLepR), the main leptin-binding protein in human blood, 
can modulate leptin effects on target organs by influencing leptin action in two 
ways: 1) by inhibiting the binding of leptin to its membrane receptors; 2) by 
increasing the availability of circulating leptin, delaying its clearance. We found 
that children affected by type 1 diabetes at diagnosis had lower circulating leptin 
and higher sLepR levels as compared to high-risk subjects and controls, which is 
consistent with the report of elevated serum sLepR in diabetic children with 
metabolic decompensation (Kratzsch et al. 2006). Low levels of leptin in subjects 
with type 1 diabetes could be partially explained by the high amount of sLepR in 
the same patients. sLepR could mask leptin epitopes and hamper detection of this 
adipokine. The behaviour of sLepR levels during diabetes progression suggests a 
potential of sLepR as an early novel marker of type 1 diabetes. This is linked to 
the finding that, during diabetes progression, sLepR levels decreased over time but 
still remained higher than in healthy controls. In addition, sLepR circulating levels 
inversely correlated with β-cells function, measured as levels of circulating fasting 
C-pep, at disease onset. This finding was not confirmed in high-risk and control 
groups (although the lack of significance could be attributed to the reduced power 
due to smaller sample size for those groups). A better understanding of the 
mechanisms controlling the leptin/sLepR axis may lead to speculate on the 
possibility to use leptin as a substitute for or a combination therapy with insulin in 
type 1 diabetes. 
The importance of our study relies upon the current lack of markers able to predict 
diabetes progression and severity in type 1 diabetes. Such markers could help 
clinicians in the choose of most appropriate therapeutic intervention, in disease 
monitoring, and in the evaluation of therapeutic efficacy, ultimately improving 
prognosis. Since type 1 diabetes is a complex multifactor disease with strong 
genetic component and significant environmental influences, a broad 
immunological assessment and multifactor algorithm to pick patterns likely 
needed to dissect the complex pathogenesis and identify key patterns of disease 
progression. By using a multivariate logistic regression analysis adjusted for age, 
BMI and the value of fasting C-peptide at disease onset, we identified here two 
specific immune cell populations, both measured at disease onset, that were 
capable to predict C-peptide secretion as a surrogates measure of β-cell mass in 
humans with type 1 diabetes. Indeed, the number of CD3
+
CD16
+
CD56
+
 T cells 
and the percentage of mDC1s were independent predictors of residual C-peptide 
secretion 12 months after diagnosis. 
Our prognostic score of the fitted model reached an AUC that was significantly 
higher than the AUC of a prognostic base model that included only age, BMI and 
fasting C-peptide measured at disease onset (p <0.001). We also provided a wide 
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range of biological correlates of disease as compared to healthy and disease-
progressing individuals. The biological correlations between meta-immunological 
parameters in subjects with mild and severe type 1 diabetes indicated that in mild-
disease patients the T cells negatively correlated with NK and B cells, both 
correlations not detectable in subjects with severe disease. An advantage of the 
current study is the multi-parametric analysis on a large, well characterized cohort 
of newly diagnosed patients with type 1 diabetes followed prospectively and 
longitudinally for 24 months. As such, this is the first comprehensive study 
associating β-cell secretion capability with circulating immune cell subsets. The 
number and percentage of mDC1s and CD3
+
CD16
+
CD56
+
 T cells were prognostic 
factors of pancreatic insulin secretion up to one year after disease onset. Finally, 
our approach could also be of valuable help to understand the molecular basis of 
slow versus fast progressors to disease and to monitor high-risk subjects towards 
the development of β-cell failure in conjunction with tests measuring the acute 
insulin response to glucose (ie. AIR-glucose) which could reflect very early an 
ongoing immune attack against insulin producing β-cells. 
In conclusion, our experimental model could represent a novel tool to monitor the 
staging of type 1 diabetes patients and may be useful, together with previously 
known parameters (i.e. glycated haemoglobin, insulin requirement), to assess 
disease progression and also contribute to define the most appropriate therapeutic 
approach according with the aggressiveness of the disease at onset. Our results 
could lead to the discovery and/or validation of biomarkers that represent early 
events in the disease as well as those that may serve as surrogate read-outs or 
endpoints for efficacy of specific interventions. 
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OBSERVATIONS
Glucose
Derangements in
Very Young Children
With Cystic Fibrosis
and Pancreatic
Insufﬁciency
C ystic ﬁbrosis–related diabetes(CFRD) is considered the mostcommon comorbidity in patients af-
fected by cystic ﬁbrosis (CF), with a prev-
alence increasing with age (1). Recently,
more attention has been turned to other
less severe glucose metabolism derange-
ments (GMD), since prediabetes may be
related to increased morbidity (1), and
early treatment may improve the clinical
course in patients with CF (2). Accord-
ing to recent guidelines released by
the Cystic Fibrosis Foundation, the
American Diabetes Association, and the
Pediatric Endocrine Society, the oral
glucose tolerance test (OGTT) is recom-
mended yearly in patients with CF over
10 years of age (3). Some authors recom-
mend annual OGTT after the age of 6
years in CF patients with pancreatic in-
sufﬁciency (4).
In order to compare the prevalence of
GMD in CF patients with pancreatic in-
sufﬁciency by age, OGTT was performed
in all CF patients.2 years of age, exclud-
ing thosewith pancreatic sufﬁciency in reg-
ular follow-up at the CF Care Center of
Federico II University in Naples in 2011.
The study population was represented by
157 patients: 84 male, 73 female; mean
age 10.5 6 3.95 years (range 2.4–18.0);
forced expiratory volume in the 1st second
886 28 (range 28–180; n5 113); 5 sub-
jects were excluded because of noncom-
pliance to OGTT. Therefore, 152 patients
were effectively studied. The study was
approved by the local ethics committee
of the University Federico II of Naples.
GMD were classiﬁed into three categories:
CFRD (glycemia $11.1 mmol/L at time
120 min [T120’]), impaired glucose toler-
ance (IGT, glycemia $7.7 mmol/L at
T120’), and indeterminate glucose toler-
ance (INDET, glycemia $11.1 mmol/L
at T30’ and/or T60’ and/or T90’ of OGTT
but,7.7 mmol/L at T120’). Prevalence of
GMD was compared among three age
groups: between 2.4 and 5.9 years (n 5
24), between 6 and 9.9 years (n5 42), and
$10 years (n5 86). Among patients aged
,6 years, 2 were CFRD, 4were IGT, and 2
were INDET (GMD 33.3%); among pa-
tients aged 6–9.9 years, 1 was CFRD, 7
were IGT, and 2 were INDET (GMD
23.8%); and among patients aged $10
years, 7 were CFRD, 22 were IGT, and 9
were INDET (GMD 44.2%); P 5 0.025
between groups aged 6–9.9 years and
$10 years.
Our results conﬁrm the high preva-
lence of GMD in CF patients with pan-
creatic insufﬁciency between 6 and 10
years (4) and provide new information on
the presence of a consistent number of
GMDs even in patients ,6 years of age,
therefore we suggest that the screening of
GMDs may be indicated from the youn-
gest age at least in those with pancreatic
insufﬁciency (4,5). It is questionable if
OGTT is the most appropriate screening
method in the youngest age. Further lon-
gitudinal studies are needed to evaluate
the prognostic role of very early diagnosis
of GMD in CF.
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Celiac disease in type 1 diabetes mellitus
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Abstract
Celiac Disease (CD) occurs in patients with Type 1 Diabetes (T1D) ranging the prevalence of 4.4-11.1% versus 0.5%
of the general population. The mechanism of association of these two diseases involves a shared genetic
background: HLA genotype DR3-DQ2 and DR4-DQ8 are strongly associated with T1D, DR3-DQ2 with CD. The
classical severe presentation of CD rarely occurs in T1D patients, but more often patients have few/mild symptoms
of CD or are completely asymptomatic (silent CD). In fact diagnosis of CD is regularly performed by means of the
screening in T1D patients. The effects of gluten-free diet (GFD) on the growth and T1D metabolic control in CD/
T1D patient are controversial. Regarding of the GFD composition, there is a debate on the higher glycaemic index
of gluten-free foods respect to gluten-containing foods; furthermore GFD could be poorer of fibers and richer of
fat. The adherence to GFD by children with CD-T1D has been reported generally below 50%, lower respect to the
73% of CD patients, a lower compliance being more frequent among asymptomatic patients. The more severe
problems of GFD adherence usually occur during adolescence when in GFD non compliant subjects the lowest
quality of life is reported. A psychological and educational support should be provided for these patients.
Keywords: Diabetes, Celiac disease, Genetic background, HLA, Dietetic compliance, Glycaemic index, Gluten free
diet, Quality of life
Introduction
Type 1 Diabetes Mellitus (T1D) is frequently associated
to other autoimmune conditions. These conditions can
severely affect clinical management of the disease, espe-
cially in paediatric age.
The most frequent are autoimmune thyroid disease
(AIT), celiac disease (CD), Addison’s disease (AD) and
vitiligo. These diseases are associated with organ-specific
autoantibodies: AIT with thyroid peroxidase (TPO) and
thyroglobulin autoantibodies (TG), CD with endomysial
(EMA) and transglutaminase (TTG) autoantibodies, and
AD with adrenal autoantibodies. Using these autoantibo-
dies, organ-specific autoimmunity may be often detected
before the development of clinical disease, in order to
prevent significant morbidity related to unrecognized
disease [1]. These diseases are very often clustered in
the same individual and a shared genetic background
probably explains this association [2].
Genetics
The majority of autoimmune endocrine diseases, includ-
ing T1D, are inherited as complex genetic traits. Multi-
ple genetic and environmental factors interact with each
other to confer susceptibility to these disorders. Genetic
risk factors associated with T1D, ATD, CD and AD
include HLA genes and non-HLA genes.
HLA DR4 and DR3 are strongly associated with T1D
and approximately 30-50% of patients are DR3/DR4 het-
erozygotes. The DR3/DR4 genotype confers the highest
diabetes risk with a synergic mode of action, followed by
DR4 and DR3 homozygosity, respectively. The HLA-DQ
(particularly DQ 2 and DQ8) locus has been found to be
the most important determinant of diabetes susceptibility.
Approximately 90% of individuals with T1D have either
DQ2 or DQ8, compared to 40% of the general population
[3]. So, the highest-risk human leukocyte antigen (HLA)
genotype for T1D is DR3-DQ2, DR4-DQ8.
DR3-DQ2 shows a strong association with CD; homo-
zygosity for DR3-DQ2 in a population with T1D carries a
33% risk for the presence of TTG autoantibodies [4].
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Non-HLA genes are also involved in the predisposi-
tion to T1D and other autoimmune diseases, such as
MIC-A, PTPN22, CTLA-4 [1].
Epidemiology
Traditional studies, both in children and adults, have
shown that CD occurs in patients with T1D with a preva-
lence that varies from 4.4 to 11.1% compared with 0.5%
of the general population (Table 1 for references from)
[5-14]. The mean age at diagnosis of classical CD is com-
monly around 2-3 years, while the mean age at diagnosis
of T1D is 7-8 years. The age at onset of T1D is younger
in patients with the double disease than in those with
only T1D [15]. The risk of CD is negatively and indepen-
dently associated with age at onset of diabetes, with an
higher risk being seen in children age < 4 years than in
those age > 9 years [16]. In patients with T1D, diabetes is
usually diagnosed first, CD precedes diabetes onset only
in 10-25% [16,17], while generally CD diagnosis in T1D
patients occurs, trough the screening performed at dia-
betes onset, in 70-80% of patients with a median age > 8
years. Some authors hypothized that in genetically sus-
ceptible patients one disease could predispose to another.
Particularly, it has been suggested that untreated (latent
or silent) CD could be an immunological trigger and
induce diabetes and/or thyroid disorders due to gluten as
a driving antigen [18]. In accordance with this, the preva-
lence of autoimmune disorders in CD is closely related to
age at diagnosis or, in other words, to the duration of
exposure to gluten [19] and thyroid-related antibodies
tend to disappear during twelve months of gluten-free
diet, like CD-related antibodies [20]. However, at present,
it is unknown whether treatment of CD reduces the like-
lihood of developing autoimmune disorders, or changes
their natural history and actually others found no corre-
lation between duration of gluten exposure in adult CD
and risk of autoimmune disorders [21].
CD clinical symptoms
The most severe CD-related symptoms are generally
related to gastrointestinal malabsorption and include mal-
nutrition, failure to thrive, diarrhea, anorexia, constipation,
vomiting, abdominal distension, and pain. These features
are more common in children younger than three years of
age. Non-gastrointestinal symptoms of CD include short
stature, pubertal delay, fatigue, vitamin deficiencies, and
iron deficiency anemia and are more commonly observed
in older children. The gastrointestinal presentation of CD
rarely occurs in T1D patients (< 10%), but many patients
with CD and T1D are either asymptomatic (silent CD) or
present only mild symptoms [17,20,22]. Furthermore, the
wide spectrum of CD include also subjects with positive
celiac-related antibodies without diagnostic small-bowel
mucosal villous atrophy. This condition is defined as
potential celiac disease (pot-CD) [23-25]. Data from the
majority of childhood diabetes care centers in Italy showed
that prevalence of pot-CD patients in this population
(higher in females than males) is 12.2%, while the preva-
lence of pot-CD in the CD control population is 8.4% and
only few of them present CD-related symptoms [26].
CD-screening
Diagnosis of CD is regularly due to screening protocols
which are widely recommended and performed. Actually
diagnosis is commonly performed by means of TTG IgA
(confirmed by EMA) or TTG-IgG if IgA-deficiency is
present. Screening has to performed at followed times:
1) at the time of diabetes onset, 2) yearly in the first 4
years of follow up, 3) each 2 years in the successive 6
years of follow up [27,28]. In the presence of CD-related
antibodies positivity it is mandatory to perform bowel
biopsy to confirm diagnosis of CD, even if in very recent
guide-lines of ESPGHAN Society [29] it is proposed that
in evident CD-cases it is possible to avoid biopsy (4
main criteria).
Table 1 Prevalence of CD in patients with T1D in recent literature (2004-2011)
Reference Country N. Age (yr) Screening Prevalence (%)
Cerutti et al. 2004 Italy 4322 11.8 ± 4.2 AGA + EMA 6.8
Contreas et al. 2004 North Italy 357 Children EMA 7
Sanchez et al. 2005 Germany 281 Children AGA + EMA 6.4
Araujo et al. 2006 Brasil 354 Children TG 10.5
Goh et al. 2007 UK 113 Children EMA + TG + AGA 4.4
Larsson et al. 2008 Sweden 300 < 20 EMA 10
Karavanaki et al. 2009 Greece 144 12.3 ± 4.6 TG 4.8
Djuric et al. 2010 Serbia 121 Mean 10.8 TG 5.79
Bhadada et al. 2011 India 189 10.81 ± 7.3 TG 11.1
Gabriel S et al. 2011 Romania 119 11 ± 4 TG 9.2
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CD-treatment
GFD should be proposed actually only in patients with
mucosal atrophy.
In patients with overt CD, identifying and treating CD
with gluten free diet (GFD) surely confer benefit in
reducing/resolving malabsorption, infertility, osteoporo-
sis, poor nutrition, impaired growth and long-term
malignancy risks and mortality rates [30-32]. Similarly,
children with T1D and symptomatic CD benefit from
GFD [33] and also metabolic control of diabetes could
be ameliorated [34].
On the contrary, in symptom-free patients weight gain
and bone mineral density (BMD) changes have been non-
univocally described as benefit [35-37]. The different view-
points highlight the need of a prolonged follow up in
patients affected by T1D and asymptomatic CD to clarify
the role of GFD. Some authors argument that GFD in
asymptomatic CD-T1D patients should be opportunely
proposed but not excessively stressed [38,39].
Finally, no definite consensus exists among experts
about to treat by GFD pot-CD patients, in whom recently
it has been suggested that GFD could be a benefit [40].
Concerning to the natural history of patients whit pot-CD,
a recent study shows that 30% of these patients develops
overt CD in a three years follow-up and underlines the
necessity of re-testing [41]. However no data are available
about the follow-up of patients with T1D and pot-CD.
Surprisingly, intestinal inflammation has been described
also in T1D patients without CD-related antibodies and
structurally normal intestinal mucosa [42]. According to
this, our group has observed a gluten-related inflammation
either in rectal either in small bowel mucosa of children
with T1D [43,44]. It can be speculated that gluten could
be an optimal candidate to stimulate an abnormal innate
immune reaction in intestinal mucosa due to its pro-
inflammatory characteristics. It remains a crucial issue to
establish if the extended intestinal inflammation in T1D is
gluten-dependent and whether it precedes the occurrence
of the disease.
Bone impairment: a hidden threat
In patients with only T1D it is possible to demonstrate
impairment of bone metabolism and structure, specially in
relationship with duration and/or poor control of diabetes
[45]. Furthermore CD also have been underlined as cause
of bone impairment. Clinical observation indicates that
clustering of three autoimmune diseases (T1D, CD and
generally thyroiditis) significantly increases the occurrence
of osteopenia (37.5%). It is possible that bone impairment
might be considered not only a complication due to endo-
crine or nutritional mechanisms, but also a consequence
of an immunoregulatory imbalance [46]. In fact osteoclasts
are now considered as the innate immune cells in the
bone, since they are able to produce and respond to
cytokines and chemokines. Bone remodelling involves
complex interactions between osteoclasts and other cells
in bone microenvironment (marrow stromal cells, osteo-
blasts, macrophages, T-lymphocytes and marrow cells)
[47]. Several cytokines, like the cytokine receptor activator
of NFkB ligand (RANKL) and the macrophage colony
stimulating factor (M-CSF), can promote osteoclast forma-
tion and activity. Also osteoprotegerin (OPG), a circulating
secretory glycoprotein, could have a role in bone remodel-
ling in children with T1D because it could promote differ-
entiation, fusion, survival, activation and apoptosis of the
osteoblasts. Alterations or abnormalities of the RANKL/
OPG system have been implicated in different metabolic
bone diseases characterized by increased osteoclast differ-
entiation and activation, and by enhanced bone resorption
[48].
In patients affected by both T1D and CD, the risk of
developing osteopenia is also influenced by the compli-
ance to GFD. In fact, osteopenia occurs more frequently
in patients with diabetes and CD with poor compliance
to GFD [49]. Recent observations indeed indicated an
imbalance of cytokines relevant to bone metabolism in
untreated celiac patients’ sera and the direct effect of
these sera on in vitro bone cell activity. In particular the
RANKL/osteoprotegerin (OPG) ratio was increased in
patients not on gluten-free diet [46].
In conclusion osteopenia seems to be a new occult
problem in CD patients, in T1D patients and in patients
with two or three immunological diseases, depending
also on GFD.
GFD composition
Diet is a fundamental part of the treatment in both T1D
and CD. However GFD composition could present some
problems for diabetic people (Table 2).
The glycemic index (GI) provides an indirect measure of
the ability of a food to raise blood glucose.GI is retained a
direct index of absorption of carbohydrates, being: “the
area under curve of blood glucose after eating a food con-
taining a determined quantity of carbohydrate”. White
bread (GI = 100) is usually compared as reference value.
In normal subjects ingestion of foods with high GI leads
to a rapid blood glucose increase causing a marked insulin
response. In diabetes, diet containing food with high GI is
Table 2 Variations of HbA1c, BMI gain and height
velocity after GFD in children with T1D-CD
Reference HbA1c BMI gain Heigh velocity
Westman et al. unchanged Unchanged unchanged
Saukkonen et al. unchanged Increased unchanged
Amin et al. reduced Increased unchanged
Saadah et al. unchanged Increased unchanged
Valletta et al. unchanged Unchanged unchanged
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considered inopportune because in condition of insulin
deficiency (T1D) or insulin inefficacy (type 2 diabetes) the
normal insulin response is not obtainable; traditionally the
common diet of the diabetes people consists principally in
foods with low GI. In 2002 American Society for Clinical
Nutrition published an international table, revised by an
older published of the sixties, which shows the GI of most
common foods, evaluated in comparison to glucose and to
white bread [50], (Table 3) where gluten-free products
have higher GI-foods than similar products gluten con-
taining. In Paker’s study [51] six types of gluten-free foods
are compared with white bread containing gluten. These
foods were eaten from 11 adult patients with type 2 dia-
betes and blood glucose was measured after eating. Results
showed no difference about GI among gluten-free foods
and those containing gluten. On the contrary, Berti et al.
show a higher blood glucose curve for gluten-free foods,
although with similar insulin curves and with contradictory
results between in vivo and in vitro analysis. (Table 4),
[52]). Specific studies both in healthy patients and in type 1
and type 2 diabetic patients should be necessary, particu-
larly in pediatric age.
In addition, gluten-free foods are prepared using corn
flour, rice and wheat, where the percentage of fiber, carbo-
hydrate, fats and micronutrients isn’t completely known.
Scarce contrasting data generally describe in gluten free
foods composition few proteins, more fat and few fibers
than gluten containing foods. (from SCHAR website and
Ministry of Agriculture website, Tables 5 and 6). In addi-
tion in the review of Kupper [53] GFD seems to can be
the cause of a multiple nutrients deficiency, especially of
vitamin B, vitamin D, calcium, magnesium, iron, zinc, but
sources of his information are not well documented.
Finally Berti et al. [52] reported higher amount of fats in
gluten-free bread then those with gluten, but the same
amount of fibers (Table 7).
Compliance/adherence to GFD and quality of
life (QOL)
Adherence to GFD among T1D-CD patients, in our
experience, is generally good in patients who experi-
enced clear clinical symptoms of CD, but is scarce
among patients with few symptoms or asymptomatic. In
Table 8 a summary of the data of literature is presented,
but authors did not specify whether patients had experi-
enced symptoms; data of our group are also presented
[36]. In contrast with T1D population, dietary compli-
ance in CD patients (without T1D), seems to be higher:
approximately 73% of patients followed the diet strictly
[54]. Probably for a patient with T1D, already engaged
in coping day by day a complex chronic disease, the
addition of a second “limiting” condition, is a remark-
able discomfort [55]. Consequently, in the case of dou-
ble diagnosis (T1D + CD), it is very difficult to manage
patients who did not experienced CD symptoms.
Studies on the compliance/adherence to GFD in non
diabetic people showed that, in relation to the social life,
children usually have a better compliance to GFD than
adults [56]. In a follow-up of 10 years in the Netherlands
conducted on children from 2 to 4 years who received CD
diagnosis by screening, authors described a general
improvement of health without deterioration in QOL [57].
In concordance Kolsteren showed that the QOL of celiac
children is quite similar to that of other children [58].
Usually the difficulty with the diet occurs when the patient
became adolescent, because she/he needs to feel equal to
peers, especially when she/he decides to go out to eat and
more acutely she/he feels limits imposed by GFD. Accord-
ing to Wagner et al. [59] celiac adolescents non compliant
with GFD reported a lower general QOL, more physical
problems, a higher burden of illness, more family troubles,
and more problems in leisure time than adolescents who
are compliant with GFD. No differences between compli-
ant patients with CD and adolescents without any chronic
condition were found in all QOL aspects.
It is also important remark that the balance between
GFD adherence and daily life is difficult to achieve for the
child/adolescent who is also affected by an other chronic
disease such as T1D. The need to coordinate insulin ther-
apy with proper nutrition and a healthy lifestyle, in order
to maintain adequate metabolic control, is already a con-
siderable effort for the young T1D-patient and families
[60]. Rebellions are frequent especially in adolescents, who
are already feeling diabetes as very “invasive” for all the
aspects of daily life and who receive a further “restriction”
constituted by the GFD. Consequently there it could be
the risk, especially if this proposal is not properly, to elicit
a response of complete rebellion which will endanger not
only the adherence to the GFD [36,54,55], but also the
entire management of T1D, causing a sharp deterioration
of general compliance and increasing the risk of severe
acute complications (recurrent ketoacidosis, unawareness
Table 3 GI of some gluten-free foods, compared to
glucose and white bread
GI glucose = 100 GI bread = 100
Gluten-free multigrain bread 79 ± 13 113
Gluten-free white bread 76 ± 5 108 ± 7
Gluten-free fiber enriched bread 73 ± 4 104 ± 5
Table 4 GI of gluten-free foods evaluated in vivo,
compared to white bread (= 100)
Food GI
Gluten-free bread 230
Gluten-free pasta 255
Quinoa 186
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hypoglycemia). In addition it is possible to think that this
further limit could be a trigger also of eating disorders in
adolescent patients, being eating disorders not rare and
previously reported in diabetes. Regarding QOL, Sud et al.
[61] in children with T1D-CD showed that the double
diagnosis appears to have a minimal impact on QOL, even
if patients’ parents reported a very important difficulty on
management. It is interesting that not significant differ-
ences in QOL were observed with regard to age at CD
diagnosis and duration, or on the basis of adherence with
a GFD. Furthermore parents of T1D-CD children did
express greater concern about their child’s social
functioning.
Conclusions
Prevalence of CD among children with T1D is signifi-
cantly higher than in non diabetic children. In a large
proportion CD is asymptomatic or characterized by
modest/atypical symptoms. Periodic screening of CD
auto-antibodies is mandatory. CD diagnosis requires the
biopsy confirmation and it is necessary to prescribe
GFD in the presence of mucosa impairment. Concerning
the clinical benefits of GFD in T1D-CD patients, data
are contrasting, except in severely symptomatic patients.
Osteopenia seems to be a new occult problem in CD
patients, in T1D patients and in patients with two or
three immunological diseases, depending also on GFD.
Table 5 Nutritional composition of gluten free and containing gluten foods
Products PROT (g) CHO (g) SUGARS (g) FATS (g) FIBER (g) KCALS
Flour 00 11 77.3 1.7 0.7 2.2 340
Gluten-free flour 1.2 86.3 1.5 0.8 4.5 357
Crackers containing gluten 9.4 80.1 2.5 10 2.8 428
Gluten-free crackers 5.2 74.7 5.2 12.7 2.9 434
Cereal flakes containing gluten 6.6 87.4 10.4 0.8 3.8 361
Gluten-free cereal flakes 8 80 5.3 16 5 361
Rusks containing gluten 11.3 82.3 2.2 8.2 3.5 408
Gluten-free rusks 4.8 82.9 5.4 1.4 3.6 425
Pasta containing gluten 10.9 79.1 4.2 2.5 2.7 353
Gluten-free pasta 9 73.7 0.4 7.9 2.2 353
Biscuits 6.6 84.8 18.5 14.3 2.6 416
Gluten-free biscuits 2.7 79.9 16.1 0.8 459
Table 6 Portion size, macronutrient and micronutrient composition of test meal.
White
bread
GF
biscuits
GF white Unsliced
bread
GF fibre Sliced
bread
GF white Sliced
bread
GF fibre Unsliced
bread
GF
pasta
Serving (g) 107 73 101 119 101 119 64
Energy (kcals) 232 335 221 225 221 236 230
Protein (g) 8.1 2.55 3.03 3.57 3.03 3.57 5.05
Carbohydrate
(g)
50 50 50 50 50 50 50
(g sugars) 3.21 17.5 4.54 5.36 4.50 5.35 0.61
Fat (g) 1.39 13.87 1.01 1.19 1.01 2.38 1.02
(g satured) 0.32 4.38 0.50 0.60 0.50 1.19 0.32
Fibre (g) 1.61 2.92 1.01 5.95 1.01 7.7 0.96
Sodium (g) 0.56 0.37 0.51 0.47 0.51 0.35 0.05
GF = gluten-free
Table 7 Weight of meal and nutrient composition of 50 g available carbohydrate portions of the foods studied as
served.
Tests foods Weight of meal (g) Protein (g) Water (g) Carbohydrate (g) Fat (g) Total dietary fibers (g)
Bread 100 9.4 31.4 50 3.6 2.8
GF Bread 125 5.7 38.5 50 9.7 3.9
Gf Pasta 156 3.2 61.2 50 0.6 2.1
Quinoa 320 3.4 75.9 50 2.0 2.8
GF = gluten-free
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It is unclear whether GFD composition could present
any disadvantages regarding of glycemic index, fibers,
percentage of fat and micro-nutrients. Data are not uni-
vocal on this point.
Communication of the need of GFD in patients with
T1D-CD is particularly delicate, especially in adolescents
where it is possible to trigger rebellion behaviors. The
coexistence of these two diseases in the same patient
requires care by clinicians and probably a specific psy-
chological approach.
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1. Introduction 
Co-morbid conditions are relatively frequent in Type 1 Diabetes Mellitus (T1DM). They can 
severely affect clinical management of the disease, especially in pediatric age.  
Furthermore, these conditions could present very interesting ethiopatogenetic mechanisms. 
2. Associated autoimmune conditions 
2.1 Genetic associations 
Patients with type 1 diabetes (T1D) have an increased risk of other autoimmune conditions, 
such as  autoimmune thyroid disease (AIT), celiac disease (CD), Addison’s disease (AD) and 
vitiligo. These diseases are associated with organ-specific autoantibodies: AIT with thyroid 
peroxidase (TPO) and thyroglobulin autoantibodies (TG), CD with endomysial (EMA) and 
transglutaminase (TTG) autoantibodies, and AD with adrenal autoantibodies. Using these 
autoantibodies, organ-specific autoimmunity may be often detected before the development 
of clinical disease, in order to prevent significant morbidity related to unrecognized disease 
(Barker, 2006). The probable mechanism of these associations involves  a shared genetic 
background (Myśliwiec et al., 2008; Smyth et al., 2008). 
The majority of autoimmune endocrinopathies, including T1D, are inherited as complex 
genetic traits. Multiple genetic and environmental factors interact with each other to confer 
susceptibility to these disorders. Genetic risk factors associated with T1D, ATD, CD and AD 
include HLA genes and non-HLA genes.  
2.1.1 HLA genes 
The major histocompatibility complex (MHC) has been extensively studied in these diseases. 
HLA molecules are highly polymorphic and multiple different peptides can be presented to 
T cells by these molecules. In general it appears that the alleles associated with 
autoimmunity are not abnormal, but functional variants, that aid in determining specific 
targets of autoimmunity. The leading hypothesis is that these molecules contribute to 
determine risk through the peptides they bind and present to T-lymphocytes, either by 
influencing thymic selection, or peripheral antigen presentation. (Ide  & Eisenbarth, 2003).  
HLA DR4 and DR3 are strongly associated with T1D and approximately 30-50% of patients 
are DR3/DR4 heterozygotes. The DR3/DR4 genotype confers the highest diabetes risk with 
a synergistic mode of action, followed by DR4 and DR3 homozygosity, respectively. The 
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HLA-DQ (particularly DQ 2 and DQ8) locus has been found to be the most important 
determinant of diabetes susceptibility. Approximately 90% of individuals with T1D have 
either DQ2 or DQ8, compared to 40% of the general population (Ide & Eisenbarth, 2003). So, 
the highest-risk human leukocyte antigen (HLA) genotype for T1D is DR3-DQ2, DR4-DQ8.  
DR3-DQ2 shows a strong association with CD; homozygosity for DR3-DQ2 in a population 
with T1D carries a 33% risk for the presence of TTG autoantibodies (Bao et al., 1999). 
Moreover, in families with multiple members affected with T1D and AIT, DR3-DQ2 has 
been linked with AIT and T1D (Levin et al, 2004). AD has been associated with the presence 
of a rare subtype of DR3-DQ2, DR4-DQ8 in which the DR4 subtype is DRB1*0404. This 
subtype is found in less than 1% of the general population compared with 30% of the 
population with AD (Barker et al., 2005; Myhre et al., 2002; Yu et al., 1999). A schematic 
representation of the HLA region and its association with T1D is shown in the Figure 1. 
 
 
(from Pugliese A. and Eisenbarth G.S., Chapter 7, Type 1 Diabetes: Molecular, Cellular, and Clinical 
Immunology, www.barbaradaviscenter.org) 
Fig. 1. The HLA Region and T1D susceptibility. Schematic representation of the HLA region 
showing microsatellite markers, loci, and alleles associated with T1D susceptibility. 
Distances between loci are grossly approximated.  
2.1.2 Non-HLA genes 
Non-HLA genes are also involved in the predisposition to T1D and other autoimmune 
diseases, such as MIC-A, PTPN22, CTLA-4 (Barker, 2006). 
Polymorphisms of MIC-A (MHC I-related gene A) have been associated with T1D, CD and 
AD. This gene encodes for a protein that is expressed in the thymus and interacts with the 
receptor NKG2D, which is important for thymic maturation of T cells (Hue et al., 2003). It is 
hypothesized that the loss of this interaction is a way in which immunological tolerance may 
be lost. NKG2D also regulates the priming of human naïve CD8+ T cells, providing an 
alternative explanation for associations with autoimmune diseases (Maasho et al., 2005).  
The PTPN22 gene is expressed in T cells and encodes lymphoid tyrosine phosphatase (LYP). 
LYP appears to be important in the signal cascade downstream from the T-cell receptor. A 
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specific polymorphism, changing an arginine to tryptophan at position 620, has been 
associated with T1D (Bottini et al., 2004; Smyth et al., 2004) and also other autoimmune 
disorders, such as rheumatoid arthritis, systemic lupus erythematosus, Graves’ disease and 
weakly with AD. The association with many autoimmune diseases suggests that this gene 
may be playing a role in susceptibility to autoimmunity in general.  
Another non-HLA gene associated with T1D which has a generic role in susceptibility to 
autoimmunity is CTLA-4 (Cytotoxic T lymphocyte-associated antigen-4) (Vaidya & Pearce, 
2004). CTLA-4 gene is an important susceptibility locus for autoimmune endocrinopathies and 
other autoimmune disorders, including T1D (Ueda et al., 2003). The CTLA-4 gene, which is 
located on chromosome 2, encodes a costimulatory molecule that is expressed on the surface of 
activated T cells. It plays a critical role in the T-cell response to antigen presentation, binding 
costimulatory molecules and inhibiting T-cell activation. (Vaidya & Pearce, 2004). The 
inhibitory effect of CTLA-4 on T-cell activation has led the investigations into its role in 
different human autoimmune disorders. Polymorphisms within the CTLA-4 gene have been 
linked to AIT (Vaidya et al., 1999). CTLA-4 has also been linked to AD and more strongly to 
subjects affected by AD in association with T1D and AIT compared with AD alone  (Vaidya et 
al., 2000). CTLA-4 has been associated with a wide range of other autoimmune disorders, 
including primary biliary cirrhosis, multiple sclerosis, CD and rheumatoid arthritis. These 
observations have suggested that CTLA-4 is a general autoimmune locus, and that the 
susceptibility polymorphisms within the gene may lead to general defects in the immune 
regulation, while other tissue-specific (e.g. insulin gene polymorphisms) or antigen-specific 
(e.g. MHC) genetic factors and environmental factors determine the involvement of particular 
target organs (Vaidya & Pearce, 2004).  
 
Gene Associated diseases 
MIC-A T1D, CD, AD 
PTPN22 AIT, AD 
CTLA-4 T1D, AIT 
Table 1. Non-HLA genes associated with T1D and other autoimmune diseases 
2.2 Type 1 diabetes and celiac disease 
2.2.1 Prevalence and age at starting 
Traditional studies, both in children and adults, have shown that CD occurs in patients with 
T1D with a prevalence that varies from 1,5 to 10 % compared with 0.5 % of the general 
population (Cronin & Shanahan, 2007; Vaarala, 2000).  The mean age at diagnosis of classical 
CD is commonly around 2-3 years, while the mean age at diagnosis of DM1 is 7-8 years. The 
age at onset of  T1D is younger in patients with the double disease than in those with only 
T1D (Kaspers et al., 2004).  The risk of CD is negatively and independently associated with 
age at onset of diabetes, with an higher risk being seen in children age < 4 years than in 
those age > 9 years (Cerutti et al., 2004). In patients with T1D, diabetes is usually diagnosed 
first, CD precedes diabetes onset only in 10-25% (Cerutti et al., 2004; Valerio et al., 2002), 
while generally CD diagnosis in T1D patients occurs, trough the screening performed at 
diabetes onset, in 70-80% of patients with a median age  >8 years. Some authors hypothized 
that in genetically susceptible patients one disease could predispose to another. Particularly, 
it has been suggested that untreated (latent or silent) CD could be an immunological trigger 
and induce diabetes and/or thyroid disorders due to gluten as a driving antigen (Pocecco & 
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Ventura, 1995). In accordance with this, the prevalence of autoimmune disorders in CD is 
closely related to age at diagnosis or, in other words, to the duration of exposure to gluten 
(Ventura et al., 1999) and thyroid-related antibodies tend to disappear during twelve 
months of gluten-free diet, like CD-related antibodies (Ventura et al., 2000).  However, at 
present, it is unknown whether treatment of CD reduces the likelihood of developing 
autoimmune disorders, or changes their natural history and actually others found no 
correlation between duration of gluten exposure in adult CD and risk of autoimmune 
disorders (Viljamaa et al., 2005).  
2.2.2 Clinical features and follow up 
The classic presentation of CD describes symptoms related to gastrointestinal malabsorption 
and includes malnutrition, failure to thrive, diarrhea, anorexia, constipation, vomiting, 
abdominal distension, and pain. This predominance of gastrointestinal symptoms is more 
common in children younger than three years of age. Non-gastrointestinal or atypical 
symptoms of CD include short stature, pubertal delay, fatigue, vitamin deficiencies, and 
iron deficiency anemia and are more commonly observed in older children. The classical 
presentation of CD can occur in T1D patients, but many patients with CD and T1D are either 
asymptomatic (silent CD) or present with only mild symptoms  (Holmes, 2001a; Ventura et 
al., 2000). Diagnosis of CD is regularly performed because screening protocols are 
universally recommended and performed. In patients with overt CD, identifying and 
treating CD with gluten free diet (GFD) surely confer benefit in reducing complications such 
as malabsorption, infertility, osteoporosis, poor nutrition, impaired growth and reducing 
long-term malignancy risks and mortality rates  (Collin et al., 2002; Freemark & Levitsky, 
2003; Rubio-Tapia et al., 2009), while no evidence exists on long-term morbidity in silent CD. 
Similarly, children with T1D with evidence of symptomatic CD benefit from GFD (Hansen 
et al., 2006; Saadah et al., 2004); in symptom-free cases the demonstrated benefit is limited to 
weight gain and bone mineral density (BMD) changes.( Artz et al., 2008; Rami et al., 2005; 
Simmons et al., 2007). Recently a 2-year prospective follow up study has provided 
additional evidence that only in some of the children with T1D and few classical symptoms 
of CD,  identified by screening as being TG+ present,  the demonstrated benefit of GFD is 
limited to weight gain and BMD changes (Simmons et al., 2011); moreover, other authors 
have reported an improved glycemic control in GFD-compliant celiac patients (Sanchez-
Albisua et al., 2005). On the contrary, silent untreated CD has no obvious effect on metabolic 
control in T1D patients, but could negatively influence weight gain (Rami et al., 2005). In 
any case, the adherence to GFD by children with T1D has been reported generally below 
50% (Acerini et al., 1998; Crone et al., 2003; Hansen et al., 2006; Saadah et al., 2004, Westman 
et al., 1999). The different viewpoints highlight the need of a long follow up of patients 
affected by T1D and asymptomatic CD to clarify the role of a GFD. Actually some authors 
argument against the need to stress GFD in nonsymptomatic T1D patients (Franzese et al., 
2007; Van Koppen et al., 2009). However, the wide spectrum of CD include also subjects 
with positive celiac-related antibodies without diagnostic small-bowel mucosal villous 
atrophy. This condition is defined as potential celiac disease (pot-CD) (Holmes, 2001b; 
Paparo et al., 2005; Troncone et al., 1996). Some authors described that the prevalence of  
pot-CD among patients with T1D recruited from the majority of childhood diabetes care 
centers in Italy is 12.2 %, with an higher prevalence of females. The prevalence of pot-CD in 
the CD control population is 8.4 % (Franzese et al., 2011). Case reports and small follow-up 
studies indicated that only few pot-CD patients may suffer from CD-related symptoms 
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before the development of villous atrophy (Troncone et al., 1996). No definite consensus 
exists among experts about to treat pot-CD patients with GFD. No data are available on the 
natural history of these patients in the long term, nor on the risks they are exposed if left on 
normal gluten-containing diet, while a recent paper provided evidence that pot-CD children 
may benefit from GFD treatment (Kurppa et al., 2010).  
Other studies have shown intestinal inflammation also in T1D patients without CD-related 
antibodies and structurally normal intestinal mucosa (Westerholm-Ormio et al., 2003).  
According to this, our group has observed a gluten-related inflammation either in rectal 
either in small bowel mucosa of children with T1D (Maglio et al,. 2009; Troncone et al., 
2003).  It can be speculated that gluten could be an optimal candidate to stimulate an 
abnormal innate immune reaction in intestinal mucosa due to its pro-inflammatory 
characteristics. It remains a crucial issue to estabilish to what the extented intestinal 
inflammation in T1D is gluten-dependent and whether it precedes the occurrence of the 
disease.  
2.3 Type 1 diabetes and autoimmune thyroid disease 
2.3.1 Prevalence and age at starting  
Antithyroid antibodies have been shown to occur during the first years of diabetes in 11-
16.9% of individuals with T1D (Kordonouri et al., 2002). Long-term follow up suggests that 
as much as 30 % of patients with T1D develop AIT (Umpierrez et al., 2003). The range of 
prevalence of AIT in patients with T1D is unusually wide (3.4-50%) (Burek et al., 1990; 
Radetti et al., 1995).  Thyroid antibodies are observed more frequently in girls than in boys, 
often emerging along during pubertal maturation (Kordonouri et al., 2005).  
2.3.2 Clinical features and follow-up 
Hyperthyroidism is less common than hypothyroidism in association with T1D (Umpierrez 
et al., 2003), but still more common than in the general population. It may be due to Grave’s 
disease or the hyperthyroid phase of Hashimoto’s thyroiditis. The presence of abnormal 
thyroid function related to AIT in the population with T1D has the potential to affect 
growth, weight gain, diabetes control, menstrual regularity, and overall well-being. In 
particular clinical features of hypothyroidism may include the presence of a painless goitre, 
increased weight gain, retarded growth, tiredness, lethargy, cold intolerance and 
bradycardia while diabetic control may not be significantly affected. Clinical features of 
hyperthyroidism may include unexplained difficulty in maintaining glycaemic control, 
weight loss without loss of appetite, agitation, tachycardia, tremor, heat intolerance, thyroid 
enlargement or characteristic eye signs.  The treatment of hypothyroidism is based on 
replacement with oral L-thyroxine (T4) sufficient to normalise TSH levels and usually this 
allows regression of the goitre if present. The treatment of hyperthyroidism is based on the 
use of carbimazole and beta-adrenergic blocking drugs, if necessary.   
There are studies showing worse diabetes control in patients with a second autoimmunity, 
including AIT and CD (Franzese et al., 2000; Iafusco et al., 1998). The factors responsible for 
the worsened control have not been completely elucidated. Thyroid dysfunction could be 
responsible of variations in absorption of carbohydrates and increased insulin resistance. 
There are studies showing similar diabetes control in patients with and without a second 
autoimmunity, in these studies thyroid autoimmunity does not lead to worsening of 
diabetic metabolic control in children with T1D (Kordonouri et al., 2002; Rami et al., 2005; 
Sumnik et al., 2006). The thyroid status is not different between diabetic patients with and 
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without CD: children with both T1D and CD do not have an increased risk of AIT 
development compared to diabetic patients without CD (Sumnik et al., 2006).  
2.4 Type 1 diabetes, Addison disease and polyglandular syndromes 
2.4.1 Prevalence and age at starting  
Addison’s disease (AD) affects approximately 1 in 10,000 of the general population. The 
autoimmune process resulting in AD can be identified by the detection of autoantibodies 
against the adrenal cortex (Anderson et al., 1957; Lovas & Husebye, 2002). Up 2 % of 
patients with T1D have antiadrenal autoantibodies (De Block et al.; 2001, Falorni et al., 1997; 
Peterson et al., 1997).  
AD is occasionally associated with T1D in the Autoimmune Polyglandular Syndromes (APS 
I and II). APS I, also known as autoimmune polyendocrinopathy candidiasis ectodermal 
dysplasia (APECED), is a rare polyendocrine autoimmune disease caused by mutations of 
the autoimmune regulator gene (AIRE) on chromosome 21q22.3 (Aaltonen et al., 1994; 
Ahonen et al., 1990), which is characterized by the association of mucocutaneous 
candidiasis, adrenal insufficiency, and/or hypoparathyroidism. Follow-up of subjects with 
this disorder has revealed that many organ systems may be involved in the autoimmune 
process including the pancreatic β cell. Approximately 20% of subjects with APS-I develop 
T1D (Barker, 2006). APS II is more common in adults, but is also observed in children in 
association with autoimmune thyroiditis (Dittmar & Kahaly, 2003). Other less common 
disorders observed in APSII include Addison’s disease, hypogonadism, vitiligo, alopecia, 
pernicious anemia and myasthenia gravis. Another rare disorder associated with T1D in 
early childhood is the Immunodysregulation Polyendocrinopathy X-linked Syndrome 
(IPEX), which is characterized also by severe enteropathy and autoimmune symptoms due 
to a clear genetic defect (FOX-P3) (Chatila et al., 2000). FOX-P3 is expressed in CD4+CD25+ 
regulatory T cells; mutations result in the inability to generate these regulatory T cells 
resulting in multiorgan autoimmunity (Barker, 2006). 
2.4.2 Clinical features and follow-up 
The condition of AD is suspected by the clinical picture of frequent hypoglycaemia, 
unexplained decrease in insulin requirements, increased skin pigmentation, lassitude, 
weight loss, hyponatraemia and hyperkalaemia. The diagnosis is based on the 
demonstration of a low cortisol, especially in response to ACTH test. Treatment with a 
glucocorticoid is urgent and life-threatening. In some cases the therapy has to be 
supplemented with a mineralocorticoid. In asymptomatic children with positive adrenal 
antibodies, detected on routine screening, a rising ACTH level suggests a failing adrenal 
cortex and the development of primary adrenal insufficiency (Kordonouri et al., 2009). There 
are no current recommendations for screening of adrenal autoimmunity.  
2.5 Type 1 diabetes and vitiligo  
Vitiligo is an acquired pigmentary disorder characterized by a loss of melanocytes resulting 
in white spots or leukoderma. The association of vitiligo with other autoimmune disorders, 
including thyroid disease, adrenal insufficiency, gonadal dysfunction, polyendocrine 
failure, diabetes mellitus, pernicious anemia, myasthenia gravis and alopecia areata, has 
been well documented (Bystryn, 1997;  Handa & Dogra, 2003). This condition is present in 
about 6% of diabetic children (Hanas et al., 2009).  Spontaneous re-pigmentation is rare and 
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not usually cosmetically acceptable. Treatment is difficult and multiple therapies have been 
tried with little success . (Ho et al., 2011) 
2.6 Type 1 diabetes and collagenopathies 
2.6.1 Rheumatoid arthritis 
The tendency of autoimmune diseases to aggregate is well known as clusters of 
autoimmune diseases within families and individuals. Analysis of susceptible genetic loci 
for the distinct autoimmune disease shows considerable overlap that suggests the possibility 
of shared pathways in their pathogenesis. Reports on the clustering of T1D, AIT, CD and 
rheumatoid arthritis (RA) in the same patient are very scarce. The major genetic 
predisposition to RA is contributed by variants of the class II HLA gene, HLA DRB1. In 
exploring the overlap between T1D, CD and RA, there is strong evidence that variation 
within the TAGAP gene is associated with all three autoimmune diseases. Relatively little is 
known about the TAGAP gene, which encodes a protein transiently expressed in activated T 
cells, suggesting that it may have a role in immune regulation. So the TAGAP gene, 
previously associated with both T1D and CD, is also associated with RA susceptibility. 
Interestingly a number of loci appear to be specific to one of the three diseases currently 
studied suggesting that they may play a role in determining the particular autoimmune 
phenotype at presentation (Eyre et al., 2010). The majority of the published case reports are 
girls. The predominance of females among the affected individuals may reflect that certain 
genes play role in the pathogenesis as gender-specific factors or the penetrance of multiple 
risk genes are enhanced in females. In most reported patients, diabetes is diagnosed first, 
thyroid autoimmunity and juvenile rheumatoid arthritis develop after a period of several 
months to years. (Nagy et al., 2010; Pignata et al., 2000; Valerio et al., 2000).  
2.6.2 Sclerodermia, systemic lupus erythematosus 
The association of T1D with Systemic Lupus Erythematosus (SLE) and Sclerodermia is rare 
but reported in literature (Inuo et al., 2009, Zeglaoui et al., 2010). Some authors found a 
significant association between DQ2 allele and the presence of anti-SSA antibodies, while 
others described an association between CD and the presence of A1B8DR3 haplotype, which 
seems to be frequent in SLE and in Sclerodermia (Black et al., 1983; Mark, 2000; Sollid & 
Thorsby, 1993). In human, the CTLA-4 and PD-1 genes significantly contributed to the 
development of various autoimmune diseases in different genetic backgrounds (Inuo et al., 
2009). ). It has been suggest the involvement of CTLA-4 and PD-1 (inhibitor receptors of 
CD28) to the development of T1D, SLE or other autoimmune diseases.  
Juvenile sclerodermia is present in 3% of sclerodermia cases, SLE in children is present in 
9% of cases of SLE; one case of a 15 years girl with CD and SLE and Sclerodermia has been 
reported (Zeglaoui et al., 2010). 
2.7 Screening for associated autoimmune disorders  
Since Type 1 Diabetes is associated with the presence of additional autoimmune disease, 
such as AIT, CD and AD, which are associated with the production of organ-specific 
antibodies, it is possible to screen patients with T1D by means of these ones. However, only 
a subset of the subjects with organ-specific antibodies develops clinical disease. The 
frequency of screening and follow up of patients with positive antibodies remain 
controversial. The current American Diabetes Association (ADA) recommendations are to 
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screen for CD-associated antibodies at diagnosis of T1D and in presence of symptoms. The 
International Society of Pediatric Adolescent Diabetes (ISPAD) recommends to screen for 
CD at the time of diagnosis, annually for the first five years and every second year 
thereafter. More frequent assessment is indicated if the clinical situation suggests the 
possibility of CD or the child has a first-degree relative with CD. Respect to the screening for 
thyroid disease, current recommendations from the ADA are for screening TSH after 
stabilization at onset of diabetes, with symptoms of hypo- or hyperthyroidism, and every 1–
2 yr thereafter. ISPAD recommends to screen by circulating TSH and antibodies at the 
diagnosis of T1D and, thereafter, every second year in asymptomatic individuals without 
goitre or in the absence of thyroid autoantibodies. More frequent assessment is indicated 
otherwise, subjects with positive TPO autoantibodies and normal thyroid function are 
screened on a more frequent basis (every 6 months to 1 yr). There are no current 
recommendations for screening of adrenal autoimmunity (Barker, 2006). Authors observed 
that the prevalence of adrenal antibodies in diabetic patients with thyroid antibodies 
compared with those without thyroid antibodies is increased (5,1 vs 0,6%) (Riley et al., 
1981).  It is possible conclude that routine screening for AD in children with T1D is not 
warranted unless there is a strong clinical suspicion or family history of AD (Marks et al., 
2003) 
 
Celiac disease Transglutaminase antibodies Yearly 
Thyroiditis TSH, FT4, thyroid antibodies Yearly 
Addison disease 
Cortisolemia, adrenal 
antibodies 
Screening if AD in family 
Collagenopathies Specific auto-antibodies No screening 
Table 2. Autoimmune diseases associated with T1D, recommended systems and frequency 
of the screening 
3. Associated non-autoimmune conditions 
3.1 Type 1 diabetes and growth 
Type 1 diabetes and other chronic diseases are well known to adversely affect linear growth 
and pubertal development, this can include a wide spectrum of different conditions, from 
poor gain of weight to Mauriac Syndrome (MS); MS classically involves hepatomegaly, 
growth impairment, and Cushingoid features in poorly controlled diabetic patients. 
Although MS, the most important expression of growth alteration due to severe insulin 
deficiency in diabetic patients, is now rare, impaired growth in children with T1D is still 
reported. This is particularly true in patients with poor metabolic control (Chiarelli et al., 
2004; Franzese et al., 2001). Some studies report that poorly controlled patients show a 
decrease in height standard deviation score over the next few years, while better controlled 
patients maintain their height advantage (Gunczler & Lanes, 1999; Holl et al., 1998).  
Longitudinal bone growth is a complex phenomenon involving a multitude of regulatory 
mechanisms strongly influenced by growth hormone (GH) (Chiarelli et al., 2004) and by the 
interaction between insulin-like growth factors (IGF-I and IGF-II), that circulate bounded to 
specific insulin-like growth factor binding proteins (IGFBPs). IGFBP-3, the major circulating 
binding protein during post-natal life, is GH-dependent. Insulin is an important regulator of 
this complex. In fact, adequate insulin secretion and normal portal insulin concentrations are 
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needed to support normal serum concentrations of  IGFs and IGFBPs and indirectly to 
promote growth. Poor gain of height and weight, hepatomegaly, non alcoholic steatosis 
hepatis  (NASH) and late pubertal development might be seen in children with persistently 
poorly controlled diabetes. Similar to healthy adolescents, the pubertal growth spurt 
represents the most critical phase for linear growth and final height in children with T1D. 
The pubertal phase is characteristically associated with reduction in insulin sensitivity, 
which is known to be more severe in patients with T1D, and might negatively influence 
growth and height gain (Chiarelli et al., 2004). Although the chronological age at onset of 
puberty and the duration of the pubertal growth spurt is not significantly different between 
subjects with T1D and healthy adolescents, several studies have shown a blunted pubertal 
growth spurt which seems to be associated with a reduced peak of height velocity SDS 
(Vanelli et al., 1992). Although loss of height from the onset of diabetes has been widely 
reported, an impaired final height has not been reported in children with T1D. In fact, while 
some studies, especially those performed in the pre-intensive insulin therapy era, showed an 
impaired final height in children with diabetes (Penfold et al., 1995), more recent studies 
show a normal or only slightly reduced final height (Salerno et al., 1997).  
The Diabetes Control and Complications Trial (DCCT) and other studies have reported 
increased weight gain as a side effect of intensive insulin therapy with improved metabolic 
control (DCCT Research Group, 1993). As obesity is a modifiable cardiovascular risk factor, 
careful monitoring and management of weight gain should be emphasised in diabetes care. 
Girls seem to be more at risk of overweight and as well of eating disorders.  
Monitoring of growth and development and the use of percentile charts is a crucial element 
in the care of children and adolescents with diabetes. Improvements in diabetes care and 
management and especially newer insulin schedules based on multiple daily injections or 
insulin pumps have led to a reduction in diabetic complications and seem to ameliorate 
growth in children with T1D. Start an intensive insulin regimen since the onset of diabetes 
might prevent the induction of abnormalities of the GH–IGF-I–IGFBP-3 axis potentially 
achieving near-normal portal insulin concentrations and thereby leading to normal IGF-I 
and IGFBP-3 levels and physiological growth in children and adolescents with T1D.  
3.2 Type 1 diabetes and eating disorders 
Eating disorders (EDs) are a significant health problem for many children and adolescents 
with T1D similar to that observed in other high risk groups, such as competitive athletes, 
models and ballet dancers. EDs and subclinical disordered eating behaviors (DEBs) have 
been described in adolescents with T1D with a higher prevalence than in a non-diabetic 
population. The start of insulin treatment and the need to comply with dietary 
recommendations both lead to weight gain, which in turn leads to body dissatisfaction and a 
drive for thinness. Since the dietary restraint usually requires ignoring internal cues of 
hunger and satiety, it has been suggested that it may be a triggering factor in the 
development of cycles of binge eating and purging. The concurrence of T1D and EDs can 
greatly increase morbidity and mortality. In diabetic subjects, EDs are associated with 
insulin omission for weight loss and impaired metabolic control. On the contrary, in a five 
year longitudinal study, the expected relationship between ED and poor metabolic control 
was not evident, although there was a trend for higher haemoglobin A1c in individuals with 
an EDs (Colton et al., 2007). This offers hope that early interventions might prevent the 
worsening  metabolic control that is often associated with EDs. In addition subclinical DEBs 
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among youth with T1D have been associated with increased risk of poor metabolic control 
and increased prevalence of microvascular complications such as retinopathy and 
nephropathy (Rydall et al., 1997). Some studies have examined the prevalence of EDs and 
DEBs in youth with T1D. Prevalence rates vary considerably from study to study possibly 
due to differences in sample, screening tools, and data collection methods. In a multi-site, 
cross sectional case-control study, the prevalence of ED meeting DSM-IV diagnostic criteria 
was about 10% and that of their sub-threshold variants about 14%: both were about twice as 
common in adolescent females with T1D than in their non-diabetic peers.  (Jones et al., 
2000). However there are also rare cases in childhood (Franzese et al., 2002a).  
3.2.1 Management 
Nutritional treatment is one of the main difficulties in managing diabetes in the young. 
Diabetes clinicians should be aware of the potential warning signs in an adolescent with 
diabetes as well as assessment and treatment options for eating disorders with concomitant 
T1D. Clinical approaches should focuse on normalizing eating behaviour and enhancing 
self-esteem based on personal attributes unrelated to weight and eating, with a low 
threshold for referral for specialized EDs services (Colton et al., 2007). A multidisciplinary 
team,  composed by clinicians, psychologist/psychiatric, dietitian/nutrition therapist, 
especially one with a background in EDs,  is opportune to identify and treat unhealthy EDs 
and DEBs in T1D. Treatment for adolescents with T1D should include both diabetes 
management treatment and mental health treatment. The diabetes team and the mental 
health team have separate responsibilities but work collaboratively to address disordered 
eating in patients with T1D. Treatment begins with emphasis on nutritional rehabilitation, 
weight restoration, and adequate diabetes control. Psychotherapy should begin immediately 
for the patient and family (S.D. Kelly et al., 2005). 
3.3 Necrobiosis lipoidica diabeticorum 
Necrobiosis lipoidica diabeticorum (NBL) is an infrequent skin affection in pediatric age. The 
etiology is not clearly understood. The reported prevalence in children varies from 0.06% to 
10% (De Silva et al., 1999). The female/male ratio is 3:1(Hammami et al., 2008). The average 
age of onset is 30–40 years. In the past, it has been described as a complication of diabetes and 
associated with microvascular complications (W.F. Kelly et al., 1993), but  NBL has been 
observed also at the beginning of diabetes. NBL typically appears on the anterior lower legs. 
The lesions are usually bilateral and are characterized by well circumscribed yellow brown 
inflammatory plaques with raised borders and an atrophic center. Ulceration occurs in up to 
35% of cases and is notoriously difficult to treat (Elmholdt et al., 2008). This complication 
negatively affects quality of life and implies a greater risk for secondary infection. Although 
NBL is usually observed in diabetic patients, there is some controversy regarding the degree of 
this association and it has been  hypothesized that the strength of this association may have 
been overestimated in the past. Some authors have studied the effect of glucose control on 
NBL and found no correlation with glycosylated hemoglobin A1c levels  (Dandona et al., 
1981), while others  found an association with a poor glucose control (Cohen et al.,  1996). 
3.3.1 Management 
There is currently no standardized effective treatment of NBL. A wide variety of treatments 
have been used over the years in adults. These include: topical, systemic or intra-lesional 
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steroids, aspirin, cyclosporin, mycophenolate, becaplermin, excision and grafting, laser 
surgery, hyperbaric oxygen, topical granulocytemacrophage colony-stimulating factor and 
photochemotherapy with topical PUVA (Hanas et al., 2009). A recent study suggests the use 
of TNF inhibitors  in selected patients for treatment of NBL (ulcerative forms) unresponsive 
to prior conventional therapies (Suárez-Amor et al., 2010). NBL in children can be hard to 
manage and may be associated with a long-term risk of malignant transformation to 
squamous cell carcinoma. Systemic therapies, such as corticosteroids and azathioprine are 
immunosuppressive and immunomodulatory and could facilitate malignant transformation 
(Beattie et al., 2006). Therefore, although NBL is not clearly related to poor metabolic 
control, we believe that the diabetic control may also be useful. Effective primary prevention 
strategies and new treatment options are needed to adequately control the disease and its 
progression. 
3.4 Osteopenia 
Children and adolescents with T1D can show several impairment of bone metabolism and 
structure, resulting in a higher risk of decreased bone mass and its related complications 
later in life. Consequently an assessment of quality of the bone through non-invasive 
methods (phalangeal ultrasonography) seems to be opportune in the care of diabetic 
patients, specially the ones with clusters of autoimmune diseases to define a possible 
involvement of the bone (Lombardi et al.,2010). 
Bone impairment in multiple autoimmune diseases might be considered not only a 
complication due to endocrine or nutritional mechanisms, but also a consequence of an 
immunoregulatory imbalance.  
3.4.1 Metabolic causes 
Alterations of bone mineral density (BMD) are especially observed when diabetes is 
associated with CD and/or AIT. Bone loss, described in patients with T1D, AIT or CD is 
usually viewed as a complication of these diseases and is related to duration of diabetes and 
quality of metabolic control. The exact mechanisms accounting for bone loss in these 
diseases have been variably explained by metabolic derangements due to the impaired 
hormonal function in T1D or AIT (McCabe, 2007), or calcium malabsorption and secondary 
hyperparathyroidism in untreated CD patients (Selby et al., 1999). Alterations of 
homeostatic mechanisms might explain an imbalance of osteoclast activity leading to 
osteopenia (Lombardi et al.,2010; Wu et al., 2008). 
3.4.2 Immune causes  
Bone remodeling involves complex interactions between osteoclasts and other cells in their 
microenvironment (marrow stromal cells, osteoblasts, macrophages, T-lymphocytes and 
marrow cells) (Kollet et al., 2007; Teitelbaum, 2007). Besides their role in calcium 
mobilization from bone and initiation of bone remodeling, osteoclasts are now considered as 
the innate immune cells in the bone, since they are able to produce and respond to cytokines 
and chemokines. Some authors found altered levels of plasma Osteoprotegerin (OPG) in 
children with T1D. Osteoprotegerin is a circulating secretory glycoprotein and is a member 
of the tumor necrosis factor receptor (TNFR) family. It works as a decoy receptor for the 
cytokine receptor activator of NFkB ligand (RANKL). RANKL and OPG are a key 
agonist/antagonist cytokine system: RANKL increases the pool of active osteoclasts thus 
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increasing bone resorption, whereas OPG, which neutralizes RANKL, has the opposite 
effect. Alterations or abnormalities of the RANKL/OPG system have been implicated in 
different metabolic bone diseases characterized by increased osteoclast differentiation and 
activation, and by enhanced bone resorption (Galluzzi et al., 2005). Therefore, bone could be 
an additional target of immune dysregulation.  
Cytotoxic T lymphocyte-associated antigen-4 (CTLA4), a well-known susceptibility gene for 
autoimmune disorders, might also represent a possible link between immune system and 
bone. In animal studies CTLA4 expressed on T regulatory (Treg) cells impairs osteoclast 
formation (Zaiss et al., 2007). Therefore the failure of Treg cell function in clustering of 
multiple autoimmune diseases could represent a mechanism to explain both the occurrence 
of poly-reactive autoimmune processes and the increase of bone resorption in the same 
individuals. 
In patients affected by both T1D and CD, the risk of developing osteopenia is probably 
influenced by the compliance to gluten-free diet. Osteopenia occurs more frequently in 
patients with diabetes and CD with poor compliance to GFD. Interestingly, recent 
observations indicate also an imbalance of cytokines relevant to bone metabolism in 
untreated celiac patients' sera and the direct effect of these sera on in vitro bone cell activity. 
In particular the RANKL/osteoprotegerin (OPG) ratio was increased in patients not on 
gluten-free diet. Actually, the only presence of a second disease, either AIT or CD, do not 
seems to increase the frequency of osteopenia, provided a good compliance to GFD in CD 
patients, while the association of three autoimmune diseases significantly increases the 
occurrence of osteopenia (37.5%). In addition, poor compliance to GFD of CD patients could 
increase the occurrence of osteopenia more in patients with three autoimmune diseases 
(80%) than in those with two autoimmune diseases (18.8%) (Valerio et al., 2008). 
3.5 Gastropathy 
Gastrointestinal motility disorders are found in a consistent proportion of children with T1D 
and are associated with significant morbidity: they are usually associated with dyspeptic 
symptoms, such as nausea, vomiting, fullness and epigastric discomfort, and could be an 
important cause of morbidity in diabetic patients. Gastroparesis has been shown to be 
significantly correlated with a poor metabolic control in a population of T1D children with 
gastric electrical abnormalities. (Cucchiara et al., 1998). Furthermore it is conceivable that 
delayed gastric emptying may cause a mismatch between the onset of insulin action and the 
delivery of nutrients into the small intestine (Rayner et al., 2001). Diabetic children with 
unexplained poor glycemic control should be investigated for abnormalities in gastric 
motility (Shen & Soffer 2000). On the other hand, hyperglycaemia itself can affect the 
neuromuscular mechanisms regulating gastrointestinal motility and delay the gastric 
emptying process (Jebbink et al., 1994). Therefore, it is of great importance to try to reverse 
abnormalities of gastric motility and improve gastric emptying in patients with T1D and 
gastroparesis by the use of domperidone in children with T1D. (Franzese et al., 2002b). 
3.6 Type 1 diabetes and limited joint mobility 
Type 1 diabetes can be associated with other less common disabling conditions of locomotor 
system: Dupuytren’s contracture, stiff hand, carpal tunnel syndrome, and limited joint 
mobility (LJM). Limited joint mobility is one of the earliest clinically apparent long-term 
complications of T1D in childhood and adolescence, characterized by a bilateral painless 
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contracture of the finger joints and large joints, associated with tight waxy skin. Changes 
begin in the metacarpophalangeal and proximal interphalangeal joints of the fifth finger and 
extend radially with involvement of the distal interphalangeal joints as well. Involvement of 
larger joints includes particularly the wrist and elbow, but also ankles and cervical and 
thoracolumbar spine (Komatsu et al., 2004). The limitation is only mildly disabling even 
when severe. With rare exception, LJM appears after the age of 10 years. The prevalence of 
LJM in T1D, evaluated in several studies ranges from 9 to 58% in paediatric and adult 
patients (Lindsay et al., 2005). 
The biochemical basis of LJM may be a consequence of changes in the connective tissue, 
probably due to alterations in the structural macromolecules of the extracellular matrix. The 
hyperglycaemia can alterate the glycation of protein with the formation of advanced 
glycation end products (AGEs), which resist to protein degradation and consequently 
increase thickness of basal membranes in the periarticular tissues (Shimbargger, 1987). 
Development of LJM is related to both age and diabetes duration (Cagliero et al., 2002), 
while others showed that it can be compromised also in a precocious age and with a short 
duration of diabetes (Komatsu et al., 2004). Of note, fluorescence of skin collagen, which 
reflects the accumulation of stable AGEs, increases linearly with age, but with abnormal 
rapidity in T1D and in correlation with the presence of retinopathy, nephropathy and 
neuropathy (Monnier et al., 1986).  
Some authors have showed that there is a clear link between upper limb musculoskeletal 
abnormalities and poor metabolic control (Ramchurn et al., 2009). It has been observed a 
reduction in frequency of LJM between the mid-70s and mid-90s in children, most likely due 
to the improved glucose control during this era (Infante et al., 2001; Lindsay et al., 2005). 
3.7 Type 1 diabetes and oedema  
Insulin oedema is a well-recognized and extremely rare complication of insulin therapy. 
It was found to occur equally in both sexes in adults, but a clear female predominance 
was noted in younger ages. The condition is self-limiting, but a progression to overt 
cardiac failure and development of pleural effusion has been reported. (Chelliah & 
Burge, 2004).  
The pathophysiology remains vague. Intensive fluid resuscitation in an insulin-deficient 
catabolic state may lead to extravasation of fluid to the subcutaneous tissue, resulting in 
peripheral oedema. This may be exacerbated by the increased capillary permeability 
associated with chronic hyperglycemia. Renal tubular sodium reabsorption is enhanced by 
insulin therapy via stimulating the Na+/K+-ATPase as well as the expression of Na+/H+ 
exchanger 3 in the proximal tubule. Transient inappropriate hyperaldosteronism has also 
been suggested to contribute to the fluid retention (Bas et al., 2010). Loss of albumin from 
the circulation due to increased transcapillary leakage probably contributed to the formation 
of oedema and the decreased serum albumin, but was not severe enough to account for the 
magnitude of oedema (Wheatly & Edwards 1985). Cases with normal serum albumin have 
also been reported.  
Clinically, insulin oedema may present with a spectrum of severity until to frank anasarca. 
Pleural effusions have uncommonly been reported, although some of these patients were 
elderly and may have had pre-existing cardiac disease. Rarely, the oedema extended from 
peripheral tissues to serosal cavities with ascites and cardiac failure (Bas et al., 2010). Fluid 
and salt restriction should be implemented and this may be all that is necessary. Diuretic 
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therapy may be indicated in more severe decompensated cases. Administration of an 
aldosterone antagonist such as spironolactone may be considered from a pathophysiological 
point of view in the presence of inappropriate hyperaldosteronism (Kalambokis et al., 2004). 
In most instances no specific therapy is needed and spontaneous recovery is noted. 
 
Impaired growth Poor metabolic control 
Monitoring of growth and 
physical development using 
growth charts 
Eating disorders Dietary restriction 
Ameliorating of nutritional 
assistance 
Necrobiosis lipoidica 
diabeticorum 
Parallel dermopathy 
Routine clinical 
examination of the skin 
Osteopenia 
Probably even present, but 
worsened by poor metabolic 
control/comorbidity 
Eventually controlled by 
Bone ultrasonography/ 
DEXA 
Gastropathy  Poor metabolic control 
Investigating of dyspeptic 
symptoms 
Limited joint 
mobility 
Parallel condition 
Routine clinical 
examination of the joint 
mobility 
Oedema Unknown Clinical examination 
Table 3. Non autoimmune associated conditions to Type 1 diabetes, causes and detection 
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